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ABSTRACT 
 
Adoptive T cell immunotherapy is a promising anti-cancer therapy that has the 
potential to become the ultimate therapeutic agents to treat a variety of diseases. Recently, 
chimeric antigen receptor (CAR) expressing T cells has demonstrated to be a very effective 
approach to treat B cell cancer patients. Despite optimistic results, there are several 
improvements that need to be made to enhance the safety and efficacy of current CAR T 
cell therapy. Fortunately, different synthetic biology tools can be implemented to overcome 
many of the current deficiencies of CAR T cell therapy. Here, we develop anti-Axl CAR 
and synNotch receptors to target Axl which is a tyrosine kinase receptor that is commonly 
overexpressed in many cancers and considered as one of important cancer therapeutic 
targets. Next, we develop a split, universal, and programmable (SUPRA) CAR system that 
can be used to switch targets without re-engineering T cells, fine-tune T cell activation 
level, and sense and logically respond to multiple antigens. These multiple features are 
useful in mitigating tumor relapse, limiting CAR-T induced toxicities, and enhancing 
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tumor specificity. Orthogonal SUPRA CARs are also used to control different cell types 
and signaling domains, enabling diverse immune responses from SUPRA CAR T cells. 
Lastly, we demonstrate that SUPRA CAR can redirect the activity of both innate and 
adaptive immune cell types. We also expand the logic capabilities of SUPRA CAR T cells 
by integrating three inputs in a single immune cell. We also show intercellular logic gate 
by engineering immune cell-cell interaction. We further demonstrate controlling 
endogenous immune cell polarization using SUPRA CAR T cells. These wide-ranges of 
SUPRA CAR applications imply its versatility as a platform for engineering cell-cell 
interactions with advanced logic functions to enhance efficacy and safety of cell-based 
cancer immunotherapy.  
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CHAPTER ONE: SYNTHETIC BIOLOGY APPROACHES TO ENHANCE 
CANCER IMMUNOTHERAPY 
 
1.1 Introduction 
 
1.1.1 Synthetic Biology Tools to Engineer Mammalian Cells 
 
Synthetic biology is a multidisciplinary field where it merges physics, biology, genetic 
engineering, chemistry, and electrical and computer engineering to program cellular 
functions more efficiently and reliably for therapeutic and research applications [1–4]. As 
synthetic biology focuses on engineering cells with novel functions that do not exist in 
nature, it has a strong emphasis on designing reliable and programmable synthetic genetic 
circuits that can provide precise control of gene of interests in a spatiotemporal manner. 
Early synthetic biology research was focused on programming synthetic gene circuits in 
prokaryotes where many of gene circuits were inspired by electrical circuits including the 
construction of genetic toggle switch [5], oscillators [6,7], and Boolean logic gates [8]. 
Many of previous gene circuits in bacteria were based on relatively simple mathematical 
models. These efforts to recapitulate the complex cellular phenotypes with simple synthetic 
components advanced our understanding of engineering cell with predictable and reliable 
functions. 
The field of mammalian synthetic biology focuses on developing tools and novel gene 
circuits to control and reprogram different functions of mammalian cells [9]. These tools 
include devices for controlling RNA and protein expression, synthetic transcription factors 
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capable of carrying out user-defined gene expression programs, tools for editing the 
genome, and tools that enable rewiring of signaling pathways. 
Many RNA devices have been developed to tune gene expression and to perform logic 
based on RNA interference or miRNAs [10,11]. Other types of RNA control devices 
include RNA aptamers and ribozymes used to regulate the stability of mRNA 
transcripts.  Additionally, synthetic biologists have created tools to control protein activity 
and turnover that could be harnessed for cellular immunotherapy. Degron domains, which 
affect the regulation of protein degradation, have been used to control the degradation 
kinetics, and thus levels, of protein in the cell [12,13]. Alternatively, ligand-inducible 
domains can be used to control the degradation or dimerization of proteins of interest in a 
tunable manner [14–16]. Recently, Lim and colleagues demonstrated the use of 
heterodimerization domains to develop CARs that can be controlled by small molecules, 
effectively creating an ON switch. Furthermore, light-inducible dimerization domains 
could be useful in cellular therapy to enable spatiotemporal control of cell activity [17–22].  
On the transcription level, there are many tools available for regulation, such as DNA 
binding domains developed by fusing natural transcription factors (e.g. TetR and GAL4) 
to transcriptional activator or repressor domains [23,24]. Synthetic transcription factors 
could also be designed to regulate endogenous transcription using zinc fingers (ZFs) 
[25,26], transcription activator-like effectors (TALEs) [27–29], or clustered regularly 
interspaced short palindromic repeat-associated systems (CRISPR/Cas) [30–32]. 
Additionally, these systems enable highly specific and efficient genome editing at defined 
genomic loci [33,34]. These tools are already being used to enhance cellular 
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immunotherapies. For example, a recent study demonstrated that CD19 CARs precisely 
integrated at the endogenous T cell receptor a-constant (TRAC) locus using CRISPR/Cas9 
resulted in uniform expression of the CAR and increased T cell potency [35]. Further, 
evidence suggests that simultaneous genomic disruption of integration of an HIV-specific 
CAR into the CCR5 locus helps engineered T cells resist HIV infection [36]. 
Another main goal of synthetic biology is to rewire cell-sensing pathways to create 
novel input-output relationships. In order to achieve this goal, synthetic receptors have 
been developed that can couple specific inputs (e.g. small molecules or surface antigens) 
with user-defined outputs (e.g. transcription programs or cell signaling) have been 
developed (Figure 1.4.1, Receptor Engineering). One of the first classes of synthetic 
receptors is activated solely by synthetic ligands (RASSLs). RASSLs are genetically 
engineered G-protein-coupled receptors (GPCRs) receptors that can respond to synthetic 
ligands with native GPCR signaling [37]. Additionally, Tango receptors have been 
developed to enable transcriptional output from three different classes of receptors 
(GPCRs, receptor tyrosine kinases, and steroid hormone receptors) [38]. Tango receptors 
tether synthetic transcription factors to the membrane using linkers containing a protease 
cleavage sequence (PCS). Upon ligand-binding, the receptor recruits a signaling protein 
fused to the appropriate protease, which subsequently cleaves the transcription factor from 
the receptor and allows it to carry out a defined transcription program. Moreover, the 
modular extracellular sensor architecture (MESA) has been used to sense soluble ligands 
through ligand-induced dimerization of a transcription factor-bearing receptor chain and a 
protease-bearing receptor chain. The MESA system has recently been used to rewire 
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human T cells to sense vascular endothelial growth factor (VEGF) and to produce 
interleukin 2 or other programmable transcriptional outputs using dCas9 system (28). This 
particular input-output function demonstrates how synthetic receptors can be used to direct 
the immune system to respond against normally immunosuppressive cues. Furthermore, 
synthetic receptors built upon a minimal proteolytic core of the Notch receptor (synNotch) 
allow for the programming of both inputs and outputs useful for cell-based therapies [39]. 
As one of key goal in synthetic biology is to engineer human cells to treat disease, the 
variety of synthetic biology tools are used to assemble more effective and precise synthetic 
gene circuits for various therapeutic purposes [4,9]. Very recently, there have been several 
foods and drug administration (FDA) approved drugs utilizing different mammalian 
synthetic biology tools. In 2017, the FDA approved the first in vivo gene therapy, Vortigern 
neparvovec, for the treatment of Leber's congenital amaurosis, which is an inherited disease 
causing progressive blindness [40]. Voretigene neparvovec is an engineered adeno-
associated virus serotype 2 (AAV2) vector that contains Retinal pigment epithelium-
specific 65 kDa protein (RPE65) cDNA. In addition, FDA approved first therapy using 
small interfering RNA (siRNA) technology to treat people with hereditary transthyretin-
mediated amyloidosis [41]. By using siRNA, it inhibits translation of abnormal form of 
transthyretin, a transport protein in the body that carries thyroid hormone and retinol-
binding protein. Also, recent clinical trials using CRISPR/Cas genome editing technology 
to treat blood disorder - thalassemia started [42]. Lastly, multiple clinical trials 
demonstrated the efficacy of using synthetic receptors called chimeric antigen receptors 
(CARs) to treat blood cancer. CD19 CAR expressing T cells or CD19 CAR-T cells have 
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been tremendously successful in treating acute lymphoblastic leukemia with complete 
remission rate up to ~90% in both children and adults. Two CD19 CAR-T cell therapies 
are now FDA approved including Novartis’ Kymriah (tisagenlecleucel) to treat acute 
lymphoblastic leukemia and Gilead’s Yescarta (axicabtageneciloleucel) to treat large B-
cell lymphoma [43]. All of these examples demonstrate applications of synthetic biology 
tools to engineer human cells to treat different diseases.  In the following section, I will 
describe the cancer immunotherapy research field in more detail and elaborate on how 
synthetic biology can be used to improve its efficacies.  
 
1.1.2 Brief Overview of Cancer Immunotherapy 
 
Immunotherapy is a type of cancer treatment that involves the use of patient 
immune systems and it is one of the most effective cancer treatment today [44,45]. There 
are several types of immunotherapy such as the use of cancer vaccines, monoclonal 
antibodies, cytokines, and adoptive cell-based therapy.  Personalized cancer vaccines have 
demonstrated to be very effective when cancer neoantigens were used in melanoma 
patients [46,47]. Cancer neoantigens are promising targets for the vaccine because they are 
highly immunogenic and tumor specific. In another example, autologous antigen 
presenting cells (APCs), which are a group of endogenous immune cells including dendritic 
cells and macrophages, have been used to treat prostate cancer. After patients’ APCs are 
collected, these isolated cells are stimulated with cancer antigen called prostatic acid 
phosphatase (PAP). Then, the APCs process and display antigens to stimulate CD4+ helper 
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cells and CD8+ cytotoxic T cells in the patient body. This therapy is called Sipuleucel-T 
(also known as Provenge) and is FDA approved to treat metastatic prostate cancer [48]. 
 Furthermore, various cytokines, small proteins that are crucial for intercellular 
signaling, are being utilized as immunotherapy agents. These cytokines include 
Interleukin-2 (IL-2) that has been successfully used to patients with advanced renal cancer 
and melanoma [49]. Also, variety of different cytokines including Granulocyte colony-
stimulating factor (G-CSF), Granulocyte-macrophage colony-stimulating factor (GM-
CSF), Interferon alpha-2b (IFN- 2b), IL-8, IL-12, and IL-15 are currently being tested in 
clinical trials to treat different types of cancers including breast cancer, ovarian cancer, 
prostate cancer, brain tumors, and Acute Myeloid Leukemia (AML) [49]. 
 Furthermore, specific types of monoclonal antibodies called checkpoint inhibitors 
have illustrated to be a very potent anti-cancer therapy [50].  Checkpoint inhibitor therapy 
targets inhibitory immune checkpoints, which downregulates immune cell function when 
activated.  Tumors often activate inhibitory checkpoint molecules on immune cells to 
protect themselves from being targeted and checkpoint inhibitors prevent interaction 
between checkpoint molecules and their ligand expressed on tumor cells. There are several 
types of FDA approved checkpoint inhibitors including CTLA-4 blockade (Ipilimumab), 
PD-1 inhibitors (Nivolumab and  Pembrolizumab), and PD-L1 inhibitors (Atezolizumab, 
Atezolizumab, and Durvalumab) [50]. These checkpoint blockers are demonstrated to be 
very effective against lung cancer, melanoma, kidney cancer, bladder cancer, and 
Hodgkin’s lymphoma. Although very promising, there are several clinical data suggesting 
that only subsets of patients get benefit from these checkpoint inhibitor therapies.  
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 Cellular immunotherapy is another pillar of immunotherapy that has shown to be 
very effective for different types of cancers [35,51–53]. Traditionally, tumor-infiltrating T 
cells (TILs) were isolated from the patient tumor, expanded ex vivo, and then re-infused 
back into patients to treat metastatic melanoma [54,55]. However, the protocol of TIL 
therapy is often complicated, time-consuming, and labor intensive. Furthermore, finding 
effective or potent TILs that will function well in vivo is not trivial. In order to overcome 
this issue, researchers have successfully re-directed T cell activity by expressing synthetic 
receptors called chimeric antigen receptors (CARs) through genetic engineering.  
CARs are genetically engineered synthetic receptors composed of extracellular single 
chain variable fragment (scFv) fused to intracellular T cell signaling domains that include 
co-stimulatory domains (such as CD28 and 4-1BB) and CD3 signaling domain [56]. 
When CAR-expressing T cells bind to tumor antigens expressed on tumor surface, they 
initiate anti-tumor immune responses such as cytokine production and tumor cytotoxicity. 
Unlike T cell receptor (TCR) activation, CAR activation is MHC-independent, but CARs 
can only target antigens expressed on cell surfaces. CAR-T cell therapy against CD19, a 
transmembrane protein expressed on B lineage cells, has shown to be very potent in 
multiple clinical trials and there are now FDA approved CD19 CAR-T cell drugs.   
It was the iteration of CAR design that really improved its clinical efficiency [56]. Early 
CAR design is composed of scFv that can bind to tumor antigens, fused to CD3 signaling 
domain. However, this first-generation CAR-T cell failed to suppress tumor burden in the 
patient. Mainly, these first generation engineered CAR-T cells lacked proliferation and 
persistence in vivo. To overcome this issue, in second generation CAR design, CD28 co-
  
8 
stimulatory domain was fused in tandem with CD3 signaling domain and this approach 
significantly increase persistence, anti-tumor effect, cytokine secretion, and proliferation 
in vivo. Later, different co-stimulatory domains such as 4-1BB are also included in CAR 
designs. In third generation CAR, multiple co-stimulatory domains were fused in tandem 
to further increase T cell functions in vivo. 
Immune cells are an ideal platform to treat different human disease for several reasons. 
First, immune cells can move through the patient body to constantly sense and signal 
pathogens or abnormal physiologies. Moreover, they can infiltrate a variety of tissue types 
and proliferate at the site of inflammation and recruit different types of immune cell types. 
In addition, they have memory phenotypes that can be crucial in recurring inflammations. 
Lastly, these immune cells can have multiple functions from cytotoxicity of tumor cells to 
secretion of cytokines that can modify local tumor microenvironments.  Thus, 
reprogramming immune cells with novel function has the potential to become the ultimate 
therapeutic agents to cure many different diseases. 
 
1.2 Current limitations of CAR-T therapy 
 
1.2.1 Safety 
 
Although very promising, CAR-T related toxicities are one of the major concerns 
in CAR-T therapy. For instance, often when patients receive CD19 CAR-T cells, they 
undergo symptom called cytokine release syndrome (CRS) [57–59]. CRS occurs when 
many of the immune cells are overactivated that can lead to the production of inflammatory 
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cytokines, which in turn can again enhance the activity of host immune cells. It is thought 
to be coming from the activation of myeloid cells by highly activated engineered T cells. 
Most of the CRS symptoms are manageable with immunosuppressive agents, but in some 
cases, it can be lethal and lead to the death of patients [60]. With recent mouse models, 
researchers are beginning to understand the mechanism of CRS in vivo [61]. To describe 
briefly, new murine models demonstrated that human or mouse macrophages interact with 
activated CAR-T cells which then activate endogenous macrophages. Activation of 
macrophages will further increase the activation level of engineered CAR-T cells to secrete 
more inflammatory cytokines.  As CRS can be toxic in a number of cases, we need a better 
CAR design to mitigate CRS toxicity in CAR-T treated patients. 
 Also, current CAR-T cells are not specific enough [62–64]. For example, CD19 is 
not only expressed on malignant B cells, but it is also expressed on normal B cells. Thus, 
when patients receive CD19 CAR- T cells, these engineered T cells will kill all the B cells 
both normal and cancer B cells. This on-target off-tumor responses lead to B cell aplasia 
in patients who receive CD19 CAR-T therapy. Although B cell aplasia is manageable with 
immunoglobulin replacement therapy, off-target of CAR-T cells can be very toxic for solid 
tumors. For instance, Rosenberg and college engineered CAR-T cells against Her2 to treat 
colon cancer. However, when the patient received Her2 CAR T cells, they reacted with 
normal lung epithelial cells that express a low level of Her2 which triggered CRS and 
eventually led to the death of patients [60]. As can be seen from this case, on-target off-
tumor response can be toxic and needs to be managed with advanced CAR design.   
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1.2.2 Efficacy 
 
Although CD19 CAR-T therapy has been very successful, multiple cases of tumor 
relapse were observed with CD19 CAR-T cell therapy that limits the efficacies of CD19 
CAR -T therapy [65–67]. That is, when patients receive CD19 CAR-T therapy, patients 
will no longer have CD19+ tumor, rather tumors evolve to express other surface proteins 
such as CD20 and CD22.  
Furthermore, even though CAR-T cell therapy is effective against blood tumor, it 
is not yet effective in treating solid tumors [68–71]. There are several problems. First of 
all, solid tumors make hard for engineered T cells to penetrate. For instance, chemokines 
and cytokines secreted by tumor cells make CD8+ T cell trafficking difficult. Also, the low 
expression level of adhesion molecules such as CXCL9 and CXCL10 in tumor cells 
prevent T cell trafficking. In addition, tumor cells have a rich extracellular matrix that 
makes T cell physically difficult to enter into tumor sites.  Even if engineered T cells are 
able to enter tumor location, they often face an array of issues compromising their 
efficacies due to tumor microenvironment (TME) [72–74].  TME makes engineered CAR-
T cell very inefficient because of hypoxia and low nutrients such as lack of glucose and 
other metabolites (e.g., adenosine) that prevent T cells from proliferating and producing 
cytokine. Furthermore, there are other immunosuppressive mechanisms including high 
inhibitory cytokines produced by cancer cells and tumor-associated macrophages (e.g., 
TGF-b, IL-4, and IL-10), expression of cell surface markers (e.g., PD-L1), and 
accumulation of regulatory T cells in TME that interfere proper T cell activations. All of 
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these mechanisms lead to a significant decrease in the efficacy of CAR-T therapy to treat 
a solid tumor.   
 
1.3 Synthetic Biology Tools for Cellular Immunotherapy 
 
1.3.1 Tools for improving safety 
 
One of the main limitations of cellular immunotherapy, particularly evident in 
using CAR T cells to treat solid tumors, is the lack of a single, sufficient tumor-specific 
antigen, which compromises both the safety and efficacy of the therapy. A dual CAR 
system that can perform combinatorial antigen detection has been developed to increase 
the specificity of the engineered T cells (Figure 1.4.1, Logic Control). In this design, one 
CAR contains the CD3 signaling domain and the other CAR contains the CD28/4-1BB 
co-stimulatory domains, such that the T cell will only respond to tumor cells that express 
both antigens. This novel strategy could help to avoid ON target, OFF tissue toxicities 
observed in CAR T cell therapy. Another example of combinatorial antigen detection uses 
the synNotch receptor to build combinatorial antigen-sensing circuits [63]. Binding of the 
synNotch receptor to the tumor antigen (dark gray) releases an intracellular transcription 
factor, which will then induce the expression of a CAR specific for a second tumor antigen. 
Furthermore, dimerizing domains that are responsive to small molecule were used to 
precisely regulate the timing and strength of T cell response [15]. 
Tumor antigen escape is another challenge that CAR T cell therapy will need to 
overcome [75]. In order to mitigate the effect of antigen escape on therapy, bispecific 
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receptors that can be triggered by CD19 and Her2 or CD19 and CD20 have been developed 
[76]. Thus, even if tumor cells are able to escape detection of one antigen through loss of 
expression, the cells will still be recognized via the second antigen. Further, many CARs 
used in clinical trials have a fixed CAR design that is impossible to alter without 
reengineering the T cells [77].  To allow for increased control over T cell activation during 
the course of treatment, several split CAR designs have been introduced [78–81] (Figure 
1.4.1. Safety Control). In these split designs, adaptor antibodies mediate binding between 
the antigen and the CAR. These split designs promote temporal control of T cell activity 
and enhance the flexibility of the therapy by allowing T cells to target multiple antigens 
without reengineering the receptors. 
Although recent multiple leukemia clinical trials with CD19 CAR T cells were 
successful, limited control over CAR T cell activity could result in severe toxicity including 
cytokine release syndrome. As the safety concerns are one of the main barriers that keep 
CAR T cell therapy from extending to other cancers than leukemia, many current CAR 
designs focus on controlling T cell activation.  One example is the use of co-inhibitory 
domains (e.g. PD-1, or CTLA-4) that enable an antigen-specific inhibitory function of the 
CAR [82].  Also, T cells were engineered to express modified human caspase-9 fused to 
human FKBP12 to allow dimerization via small molecule. Dimerization induces apoptosis 
of engineered T cells by activating human caspase9 [83,84]. Introduction of this kill switch 
will increase the safety of T cell therapy (Figure 1.4.1. Safety Control). 
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1.3.2 Tools for improving efficacy 
 
 
In addition to safety and specificity concerns, the efficacy of cellular 
immunotherapies is limited by the inability of engineered T cells to migrate through solid 
tumors, particularly in solid tissues with deformed vasculature (Figure 1.4.1. 
Effectiveness Control). In order to increase the migration of T cells to tumors, T cells 
were engineered to express the chemokine receptor CXCR2. These engineered T cells 
showed enhanced localization to tumors expressing the chemokine CXCL1 in vivo[85]. 
Moreover, this trafficking resulted in significantly improved antitumor efficacy in 
vivo[86].  T cells engineered with photoactivatable chemokine receptor, PA-CXCR4, also 
showed enhanced directional migration to tumor sites and significantly reduced tumor 
burden in vivo[87]. Another approach to enhancing engineered T cell migration involves 
restoration of heparanase expression. Ex vivo expanded T cells were found to underexpress 
heparanase, an enzyme which promotes the degradation of the extracellular matrix. T cells 
engineered to express heparanase demonstrated improved tumor penetration and antitumor 
activity[88]. 
 
In the tumor microenvironment, there are many immunosuppressive cues including 
inhibitory cytokines (e.g. IL-4 and TGF-B) and cell surface markers (e.g. PD-L1) that 
inhibit the antitumor activity of engineered T cells. Thus, engineering T cells to overcome 
these immunosuppressive cues will be critical to effective cancer cellular immunotherapy 
(Figure 1.4.1.  Effectiveness Control). In one study, blockade of inhibitory TGF-B 
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signaling through overexpression of a non-functional TGF-B receptor mitigated inhibitory 
effects[89]. Other approaches include converting immunosuppressive cues into 
immunostimulatory responses. For example, a fusion of the inhibitory cytokine receptor 
IL-4 exodomain to the IL-7 receptor endodomain effectively converted the tumor-derived 
IL-4 inhibitory pathway to IL-7 immune stimulation [90]. T cells have also been 
engineered to express receptors that comprise the PD-1 exodomain and CD28 endodomain. 
With this approach, binding of engineered T cells to PD-L1(+) tumor cells resulted in 
increased cytokine secretion and proliferative capacity of the engineered cells 
[91].  Furthermore, tumor-specific T cells have been engineered to conditionally secrete 
immunostimulatory cytokines (e.g. IL-12) in the tumor microenvironment to promote 
engineered T cell efficacy [92]. However, recent clinical trials indicate a need for better 
control of IL-12 secretion via novel gene circuit design as it showed severe toxicity in a 
clinical setting [93]. Lastly, feedback control has been used to regulate the duration and 
dynamics of the T cell response (Figure 1.4.1. Dynamic Control). 
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1.4 Figure 
 
Figure 1.4.1. Applications of synthetic biology in cancer cellular immunotherapy  
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(A) Receptor Engineering: Different synthetic receptor designs developed to reprogram 
cells with user-defined input-output relationships. 
(B) Logic Control: Different CAR receptor designs that can perform logic to enhance tumor 
specificity or to tune T cell activity. 
(C) Safety Control: Different CAR designs that can mitigate CAR- T cell-related toxicities. 
(D) Efficacy Control: Development of novel gene circuits or CARs to increase the 
effectiveness of CAR T cell therapy by engineering T cell mobility or mitigating 
immunosuppressive cues in cancer microenvironment. 
(E) Dynamic Control: Engineering cells with gene circuits that can tune T cell activation 
and its duration. 
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CHAPTER TWO: ENGINEERING AXL SPECIFIC CAR AND SYNNOTCH 
RECEPTORS FOR CANCER THERAPY  
 
 
2.1 Introduction 
 
Receptor tyrosine kinases (RTKs) are transmembrane proteins that sense extracellular 
ligands. Ligand engagement induces receptor dimerization, which leads to activation of 
downstream signaling pathways.  RTKs regulate a wide range of cellular processes such as 
cell survival, growth, and differentiation. Moreover, mutation or dysregulation of RTKs 
has been implicated in many diseases including cancer [94,95].   
The Axl protein is a member of the TAM (TYRO3, AXL, and MER) of receptor 
tyrosine kinases subfamily and involved in the stimulation of cell proliferation [96].  The 
Axl receptor has been demonstrated to be overexpressed in many human cancers including 
breast, lung, colon, and pancreatic cancers.  High level of Axl expression is associated with 
poor prognosis in different types of cancer [97–100]. Oncogenic Axl signaling increases 
cancer cell survival, migration, and invasion [101].  Dysregulation of Axl signaling is also 
known to enhance the epithelial-mesenchymal transition (EMT) and cause drug resistance 
to immunotherapy and chemotherapy [102–105].  Since Axl is implicated in many cancer 
progression and drug resistance, a therapeutic that targets Axl could be a valuable cancer 
therapy.  As such, antibody, small molecule inhibitors, and Axl receptor decoy are in the 
preclinical and clinical stage for breast, lung for other advanced solid tumors [106].  
The transfer of tumor-targeting T cells to patients is a promising approach for cancer 
immunotherapy.  In such an approach, T cells are isolated from the patient, and tumor-
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specific receptors such as chimeric antigen receptors (CARs) are introduced into the T cells 
to redirect their specificity.  CARs are composed of an antigen-specific scFv and 
intracellular signaling domains (CD3 and co-stimulatory domains).  The binding of scFv 
to an antigen on cancer cells will stimulate T cell receptor and co-stimulatory pathways, 
leading to the activation of T cells.  CAR-expressing T cells have demonstrated 
unprecedented efficacy against acute lymphoblastic leukemia (ALL), with around 90% 
complete remission being observed in clinical trials [107–110].  Despite these encouraging 
results and the recent FDA approval of anti-CD19 CAR T cells for ALL and lymphoma, 
more antigen-specific CARs are needed to treat cancer beyond B-cell malignancies.  
Therefore, the development of CAR against Axl could expand the therapeutic range of 
CAR T cell therapy.   
More recently, Lim and colleagues have created a novel receptor design called 
synNotch that enables the programming of both input and output via the release of 
intracellular transcription factor upon antigen-receptor binding [39,63].  Unlike 
conventional CAR activation which triggers endogenous T cell receptor signaling pathway 
[56,111], synNotch receptor uses the regulatory notch core portion with an engineered 
transcription factor that enables programmable inputs and outputs to perform user-defined 
functions. Because of high programmability, synNotch has been used to reprogram human 
primary T cell responses both in vitro and in vivo for enhancing tumor specificity and 
delivering therapeutic payloads in a tumor antigen-specific manner.  As such, synNotch 
receptor targeting Axl ligand with different output functions, such as producing a defined 
set of cytokines, will improve cellular immunotherapy to treat various cancers.  In this 
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study, we designed a humanized single-chain variable fragment (scFv) against Axl.  Using 
our Axl scFv, we engineered an Axl CAR and Axl synNotch receptors. In an in vivo setting, 
we demonstrated Axl CAR in human primary T cells for killing tumor cells and Axl 
SynNotch receptor for producing IL-10 in an antigen-specific manner. 
 
2.2 Results 
2.2.1 Design and Characterization of the humanized Axl CAR 
 
Since the receptor tyrosine kinase, Axl, is overexpressed in many different types of 
cancer, we tested if we can design a humanized single-chain variable fragment (scFv) 
against Axl that can be used for cellular immunotherapy, especially in the context of CAR 
and synNotch receptor. From a previously published humanized Axl antibody sequence, 
we designed an Axl scFv by fusing a variable region of heavy chain to light chain through 
a GS linker [97,112]. We first tested the functionality of the Axl scFv by using it to create 
an Axl CAR.  The Axl CAR is comprised of the Axl scFv and CD8α hinge region as the 
extracellular domain, and CD28, 4-1BB, and CD3 as the intracellular signaling domains 
(3rd generation CAR [56,113])(Figure 2.6.1A). To verify the activity of the Axl CAR, we 
stably integrated Axl CAR in Jurkat T cells genome through the electroporation of the 
PiggyBac transposon system [114].  This Jurkat T cell line also contains an NFAT promoter 
driving GFP expression for measuring CAR activation.  NFAT is a representative 
transcriptional factor that is known to be activated after T cell receptor (TCR) 
activation[113].  Therefore, NFAT transcription response is used to measure T cell 
activation by Axl CAR. After Axl CAR-expressing Jurkat T cells were stimulated with 
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plate-bound Axl protein, Axl CAR-expressing Jurkat T cells displayed a high level of 
CD69, which is an early T cell surface activation marker [115], and NFAT transcription 
reporter activity measured by GFP expression (Figure 2.6.1B). In contrast, Jurkat T cells 
without Axl CAR did not yield high CD69 and NFAT reporter expression.  
To test Axl CAR activation under a more physiologically relevant condition, we 
engineered K562 myelogenous leukemia cells to express the Axl antigen.  Axl CAR-
expressing Jurkat T cells were then co-cultured in vitro with Axl+ K562 cells (Figure 
2.6.2A).  Axl+ K562 cells activated Axl CAR-expressing Jurkat T cells strongly as 
measured with CD69 and NFAT transcription reporter expression.  However, Axl CAR T 
cells were not activated by Axl- K562 cells (Figure 2.6.2B). Furthermore, the basal activity 
of Axl CAR was minimal as measured by both CD69 and NFAT transcription reporter 
expression (Figure 2.6.2B). 
 
2.2.2 Characterization of Axl CAR in Human Primary CD8+ T cells 
 
After characterizing Axl CAR in Jurkat T cells, we tested whether our Axl CAR is 
active in human primary T cells.  Human primary CD8+ T cells were engineered to express 
the Axl CAR through lentiviral transduction, and we verified via flow cytometry analysis 
that more than 80% of the cells expressed the Axl CAR (Figure 2.6.5A).  To determine 
whether the Axl CAR is functional in CD8+ T cells, the engineered T cells were activated 
with plate-bound Axl. High CD69 expression on the T cells confirmed that Axl CAR T 
cells could be activated from plate-bound Axl protein (Figure 2.6.3A).  Next, we tested if 
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engineered T cells can eliminate Axl+ tumor cells.  We co-cultured Axl CAR T cells with 
target cells (Axl- or Axl+ K562) (Figure 2.6.3B).  Forward- and side- scatter FACS plots 
of the cell mixture after 24 hours co-culture of T cells with K562 tumor cell showed that 
Axl CAR-expressing CD8+ T cells could kill Axl+ tumor cells efficiently (Figure 2.6.3C 
left).  However, Axl CAR-expressing T cells did not kill Axl negative target cells (Figure 
2.6.3C right). Consistent with this result, live K526 cell counts, which were gated by 7-
AAD-negative and fluorescent markers, decreased only in the co-culture of Axl CAR T 
cells with Axl+ K562 cells (Figure 2.6.5B).  Furthermore, we tested the killing efficiency 
against Axl expressing Jurkat T cells, and Jurkat T cells were killed by Axl CAR-
expressing CD8+ T cells in a dose-dependent manner (Figure 2.6.5C). Importantly, Axl 
CAR T cells also killed endogenous Axl-expressing tumor cells, such as SK-OV-3 an 
ovarian cancer cell line, demonstrating the clinical relevance of Axl CAR (Figure 2.6.3D).  
We next tested cytokine secretion and verified that Axl CAR-expressing human primary 
CD8+ T cells secreted a high level of IFN- and IL-2 only when they were co-cultured 
with Axl+ K562 tumor cells (Figure 2.6.3E). 
 
2.2.3 Design and Characterization of the humanized Axl SynNotch 
 
Recently, Lim and colleague demonstrated the use of synNotch receptors for 
cellular immunotherapy applications [39,63].  Here, we tested if the Axl scFv can be 
utilized to generate a functional synNotch receptor.  The Axl synNotch receptor is 
composed of the Axl scFv as the extracellular domain and notch core region fused to 
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engineered transcription factor (tTA) (Figure 2.6.4A).  Jurkat T cells were engineered to 
stably express Axl synNotch receptor using electroporation and piggyBac transposon-
based system.  The expression of the Axl SynNotch was verified by -myc cell surface 
staining with flow cytometry (Figure 2.6.4B).  A reporter construct that composes of a tTA 
responsive promoter followed by a gene of interest (e.g., a blue fluorescent protein (BFP) 
or IL-10) were also introduced into Jurkat T cells [39,63,116].  IL-10 was chosen as an 
output because lL-10 is an inhibitory cytokine that can be used to control inflammation 
(O’Garra et al., 2008: Roybal et al. 2017). When Axl synNotch expressing T cells engage 
with tumor cells that express Axl, the tTA transcription factor is cleaved from the synNotch 
and translocated into the nucleus to regulate gene expression from the reporter.  
To test the functionality of the Axl synNotch receptor, Axl synNotch-expressing Jurkat 
T cells were stimulated with plate-bound Axl protein, and BFP expression from the 
synNotch transcription reporter was quantified.  Interestingly, the dose-response curve of 
the Axl synNotch receptor displayed a Bell curve characteristic, with maximum activation 
occurring at ~100ng of Axl protein (Figure 2.6.4C).  We also tested if Axl synNotch 
receptor could be activated with tumor cells that express Axl (Figure 2.6.4D).  Jurkat T 
cells expressing the Axl synNotch were activated and produced BFP only when co-cultured 
with Axl+ K562 tumor cells for 24hr (Figure 2.6.4E), whereas cells containing tTA 
responsive element without the Axl SynNotch did not have high BFP expression (Control, 
Figure 2.6.4E) even when co-cultured with Axl+ tumor cells.  Consistently, Jurkat T cells 
that were transiently transfected with tTA responsive IL-10 reporter showed a similar 
result, activating and secreting IL-10 only when co-cultured with Axl+ tumor cells (Figure 
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2.6.4F).  Note that the basal activity of Axl synNotch is minimal when compared to Axl- 
K562 cell condition and no target cell condition.  These results demonstrate the potential 
cellular immunotherapy application using Axl synNotch receptor. 
 
2.3 Discussion 
 
Genetic engineering of T cell for cellular immunotherapy application has become a 
promising cancer therapeutic approach.  While multiple clinical trials against B cell 
malignancies have shown encouraging results, CARs that target antigens overexpressed in 
other cancers besides B cell tumors are still needed.  In addition to CARs, the recently 
developed synNotch receptor have displayed novel therapeutic capabilities by enabling 
programmable T cell responses such as user-defined cytokine secretion, T cell 
differentiation, and local delivery of therapeutic antibodies.  However, only anti-CD19, 
GFP, or Her2 synNotch receptors have been explored.  In this study, we developed a 
humanized Axl scFv from previously reported Axl monoclonal antibody by fusing variable 
region of heavy and light chain via a polypeptide linker.  Using this Axl scFv, we 
successfully created the first Axl CAR and synNotch receptor, which can be valuable 
therapeutic reagents since Axl is overexpressed in many cancers including colon, breast, 
prostate, pancreatic and lung cancers.   
The anti-Axl CAR and synNotch behaved mostly as expected.  To demonstrate the 
clinical potential of our Axl receptors, further studies in animal models will be required.  
Interestingly, we demonstrated that Axl synNotch receptor can be strongly activated by 
plate-bound Axl protein and observed that optimal activation of Axl synNotch receptor 
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occurred when Axl protein was plated at 100ng/well. Moreover, we showed that Axl 
synNotch receptor expressing Jurkat T cells could be activated by Axl+ tumor cells.  
Although not investigated in this study, we observed that the activation of Axl SynNotch 
is much stronger with plate-bound Axl than cells expressing Axl. We hypothesize that such 
discrepancy may be due to the suboptimal expression level of Axl on tumor cells. 
Furthermore, the surface stiffness (plastic vs. cell membrane) could also be a contributing 
factor since Notch receptor is known to be regulated by force [117–119].  
 
2.4 Conclusion 
 
Here we developed a humanized Axl scFv that can be exploited in the design of CAR 
and synNotch receptors.  We validated the function of Axl CAR by demonstrating that 
human primary T cells expressing Axl CAR can effectively kill Axl+ tumor cells.  We 
further showed the therapeutic potential of Axl scFv by designing a functional Axl 
synNotch receptor that can produce IL-10 when activated by Axl+ tumor cells. In further 
studies, Axl CAR and Axl synNotch expressing T cells can be tested in mouse xenograft 
studies to test in vivo efficacy. 
2.5 Methods 
2.5.1 Humanized single chain variable fragment (scFv) against Axl design 
Humanized scFv against Axl was derived by fusing a variable region of an immunoglobulin 
heavy chain to the variable region of the light chain through a polypeptide linker (GS 
linker). Humanized heavy and light chain sequences were obtained from a previously 
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published sequence. 
 
2.5.2 Axl CAR/synNotch construct design 
Axl CAR was designed by fusing humanized Axl scFv to the hinge region of the human 
CD8α chain and transmembrane and cytoplasmic regions of the human CD28, 4-1BB, and 
CD3 signaling endodomains. They were under SFFV promoter for primary T cell 
experiments and under CAG promoter for Jurkat cell experiments. Axl synNotch receptor 
was designed by fusing humanized Axl scFv to the notch core intracellular domain fused 
to the tTA transcription factor.  Both Axl CAR and Axl synNotch contain a myc tag for 
verifying surface expression.  Furthermore, the Axl CAR used in human primary T cell 
experiments was fused to a mCherry after the CD3 chain for expression level 
quantification.  The Axl CAR used in Jurkat experiments was cloned into the piggyBac 
vector (System Bioscience Inc.), which has been modified by replacing the CMV promoter 
with a CAG promoter. 
 
2.5.3 Primary Human T cell Isolation and Culture 
Whole peripheral blood was obtained from Boston Children’s hospital, as approved by the 
University Institutional Review Board (IRB) approved consent forms and protocols. 
Primary human CD8+ T cells were isolated from anonymous healthy donor blood by 
negative selection (STEMCELL Technologies #15063). T cells were cultured in human T 
cell medium consisting of X-Vivo 15 (Lonza), 5% Human AB serum (Valley Biomedical 
#HP1022), 10 mM N-acetyl L-Cysteine (Sigma-Aldrich #A9165), 55uM 2-
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mercaptoethanol (Thermo Scientific #31350010) supplemented with 50 units/mL IL-2 
(NCI BRB Preclinical Repository). T cells were cryopreserved in 90% heat-inactivated 
FBS and 10% DMSO.  
 
2.5.3 Lentiviral Transduction of Human T cells 
Replication-incomplete lentivirus was packaged via transfection of HEK 293 FT cells 
(Invitrogen) with a pHR transgene expression vector and the viral packaging plasmids: 
pMD2.G encoding for VSV-G pseudotyping coat protein (Addgene #12259), pDelta 8.74 
(Addgene#22036), and pAdv (Promega). One day after transfection, viral supernatant was 
harvested every day for 3 days and replenished with pre-warmed Ultraculture media 
(Lonza #12-725F) supplemented with 2mM L-glutamine, 100U/ml penicillin, 100ug/mL 
streptomycin, 1mM sodium pyruvate, and 50mM sodium butyrate. The harvested virus was 
purified through ultracentrifugation or Lentivirus concentrator (Takara #631232). Primary 
T cells were thawed 2 days before ultracentrifugation and cultured in T cell medium 
described above. One day before ultracentrifugation, T cells were stimulated with Human 
T-activator CD3/CD28 Dynabeads (Thermo Scientific #11132D) at a 1:3 cell: bead ratio 
and cultured for 24 hr. After viral supernatant purification, rectronectin (Clontech #T100B) 
was used to transduce cells. Briefly, non-TC treated 6-well plates were coated with 
rectronectin following the supplier’s protocol.  Concentrated viral supernatant was then 
added to each well and spun for 90 min at 1200xg.  After centrifugation, viral supernatant 
was removed and 4ml of human T cells at 250k/ml in T cell growth media supplemented 
with 100U/ml of IL-2 was added to well. Cells were spun at 1200xg for 60 min and moved 
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to an incubator at 37 ºC.   
 
2.5.4 Cancer Cell Lines 
The cancer cell lines used were K562 myelogenous leukemia cells (ATCC # CCL-243) 
and Jurkat T cells. K562 and Jurkat T cells were cultured in RPMI-1640 (Lonza#12-702Q) 
with 5% (v/v) heat-inactivated FBS, 2mM L-glutamine, 100U/ml penicillin and 100ug/mL 
streptomycin. Jurkat and K562 were electroporated or transfected with PiggyBac 
Transposon system (System Biosciences) to stably express Axl CAR, Axl synNotch 
receptor or surface antigen: AXL. Two days after transfection, antibiotic (Puromycin 
(Thermo Scientific #A1113803), zeocin (Thermo Scientific # R25005), or Hygromycin B 
(Thermo Fisher #10687010)) was added to the medium to select for cells that express the 
transgenes.  
2.5.5 T cell activation by plate-bound antigen 
Recombinant human Axl protein (R&D #154-AL-100) was coated on 96 well plate (flat 
bottom) overnight at 4 Cº. Next day, the plate was washed with PBS three times to remove 
unbound Axl protein. Then, 200x103 Jurkat T cells or human primary T cells engineered 
to express Axl CAR or Axl synNotch were added to each well. After 24hr, for Axl CAR 
experiment, Jurkat or primary human CD8+ T cells were stained with α-CD69-APC (BD 
bioscience #340560) to measure CD69 expression level. GPF expression level driven form 
NFAT promoter was shown as NFAT promoter activity. For Axl synNotch experiment, 
BFP expression was measured as a tTA promoter reporter. 
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2.5.6 Co-culture experiments 
Jurkat T cells or primary T cells expressing Axl CAR (200 x 103 cells/well/200ul) were 
incubated with K562 target cells (100 x 103 cells/well) or with SK-OV-3 cells (100 x 103 
cells/well) at an E:T ratio of 2:1 or 1:1. For suspension cells, effector cells and target cells 
were mixed at the same time as seeding. For adherent cells (SK-OV-3), SK-OV-3 cells 
were pre-cultured for 12hr. Then, Axl CAR T cells were added to wells. After 24 hr of co-
culture, the supernatant was harvested and followed the supplier’s protocol to determine 
IFN-γ, IL-2, IL-10 level. Cytokine release assays were carried out using IFN-γ, IL-2, or 
IL-10 ELISA Kit (BD Biosciences #555142, #555190, #555157). For detection of 
activation of T cell, expression CD69, GFP, and BFP were measured use Attune NxT flow 
cytometry (Thermo). 
2.5.7 Cytolysis assay 
Two hundred thousand primary T cells expressing Axl CAR and control CD8 T cells were 
incubated with K562 target cells or SK-OV-3 cells (100 x 103 cells/well). After 24 hr co-
culture, the number of live K562 cells was counted by Attune NxT flow cytometry 
(Thermo). Live K562 cells were identified as 7-AAD-GFP+BFP+ cells. For detection of 
live SK-OV-3 after 24 hr co-culture, non-adherent cells were washed out, and adherent 
cells were stained with Calcein AM using LIVE/DEAD Viability/Cytotoxicity Kit 
(Thermo # L3224), following manufacturer’s protocol. For detection of cell-cell contact 
independent cytolysis activity, Axl-expressing K562 cells were incubated with conditioned 
medium from K562 cytolysis experiments described above. After 24 hr, the number of live 
K562 cells was counted by Attune NxT flow cytometry. For Jurkat cell targeting cytolysis 
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assay, indicated number of Axl CAR-expressing primary T cells (0, 12.5 x103, 25 x103, 50 
x 103, 100 x 103, 200 x103 cells) were cultured with 100 x103 Axl+ luciferase+ Jurkat cells 
for 4 hr. Culture medium was removed, and cells were resuspended with 50 ul/well of 2% 
FBS in PBS and lysed with 50 ul/well luciferin reagent (Promega #E2610). Lysates were 
transferred to 96-well plate (Corning #3904), and luminescence was measured with the 
SpectraMax M5 (Molecular Devices). 
 
2.5.8 Cell surface protein staining 
After 24 hr stimulation, engineered Jurkat cells and primary T cells were stained with anti-
CD69-APC antibody (BD bioscience #340560) for 30 min at room temperature. For 
detection of expression of cell surface synNotch, transfected Jurkat cells were stained with 
anti-Myc-PE (Santa Cruz Biotechnology, sc-40) for 30 min at room temperature. 
Fluorescence was measured by Attune NxT flow cytometry. 
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2.6 Figures 
 
 
 
Figure 2.6.1. Design and characterization of the Axl CAR  
 (A) Humanized Axl CAR is composed of a humanized Axl scFv as the extracellular 
domain and CD28, 4-1BB, and CD3signaling domain as the intracellular domain. (B) 
The NFAT promoter activity and CD69 expression levels of Axl CAR-expressing Jurkat 
T cells after 24hr of culturing with different amount of plate-bound Axl protein. WT NFAT 
T cells indicate Jurkat T cells harboring an NFAT reporter without the Axl CAR. Data are 
representative of three biological replicates and presented as the mean ± standard deviation 
(SD). 
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Figure  2.6.2. Axl CAR activation via cell-cell interaction 
 (A) Axl CAR-expressing or wild-type NFAT Jurkat T cells were co-cultured in vitro with 
Axl+ or Axl- K562 cells. (B)  The NFAT promoter activity and CD69 expression level 
were measured after Axl CAR-expressing Jurkat T cells, and Axl+ K562 cells were co-
cultured for 24 hr. Data are representative of three biological replicates and presented as 
the mean ± SD. 
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Figure  2.6.3. Characterization of Axl CAR in human primary CD8+ T cells 
 (A) The CD69 expression level measured after 24hr of culturing Axl CAR-expressing 
CD8+ T cell with a different amount of plate-bound Axl protein. (B) Schematics of cell 
killing against K562 target cells by Axl CAR-expressing CD8+ T cells. (C) Forward- and 
side- scatter FACS plots of the cell mixture after 24hr co-culture of T cells (blue) with 
target cells (orange). (D) Killing assay against SK-OV-3. Fluorescence of Calcein AM was 
used to quantify live SK-OV3 cells after 24hr co-culture with T cells. (E) IFN- and IL-2 
measurement after 24hr co-culture of human primary CD8+ T cells with Axl expressing 
target cells (K562). Data are representative of three biological replicates and presented as 
the mean ± SD. 
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Figure  2.6.4. Design and characterization of Axl synNotch in human Jurkat T cells 
 (A) Axl synNotch design. TF, transcriptional factor (tTA); TFBD, transcriptional factor 
binding domain. (B) The expression level of the Axl synNotch in Jurkat T cells. The myc-
tag was stained with an anti-myc antibody for the measurement of surface synNotch 
expression. Control indicates non-transfected Jurkat cells that containing only tTA 
responsive reporter. (C) Axl synNotch response from plate bound Axl protein activation. 
Control indicates Jurkat T cells harboring synNotch responsible BFP reporter without Axl 
synNotch. (D) Axl synNotch activation via co-culturing of Axl+/Axl- K562 target cells. 
(E) BFP fluorescence level after co-culturing of Axl synNotch expressing Jurkat T cells 
with target K562 cells for 24hr. Control indicates Jurkat T cells harboring only BFP 
reporter without Axl synNotch receptor. (F) IL-10 production level when co-cultured 
Jurkat T cells harboring tTA responsive IL-10 reporter cells with K562 cells for 24hr. 
(None, no target cell or no effector cell condition. N.D., not detected: Data are 
representative of three biological replicates and presented as the mean ± SD). 
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Figure  2.6.5. Human primary CD8 T cells expressing Axl-CAR show effective in 
vitro cytotoxicity against Axl+ target cancer cells.   
(A) Axl CAR expression level in human primary CD8+ T cells. (B) Killing assay against 
K562. Live K562 cells were counted by flow cytometry analysis. The graph indicates the 
ratio to live K562 cells in the condition of co-culture with WT T cells. (C) Killing assay 
against Jurkat cells. Axl+ and Axl+ Jurkat cells express luciferase. Graph indicates the 
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percentage to the luminescence in no effector T cell condition. Co-culture was performed 
in the indicated ratio of effector and target (E:T) for 4 hr. Data are representative of three 
biological replicates and presented as the mean ± SD. 
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CHAPTER THREE: UNIVERSAL CHIMERIC ANTIGEN RECEPTORS FOR 
MULTIPLEXED AND LOGICAL CONTROL OF T CELL RESPONSES 
 
 
3.1 Introduction 
 
The transfer of CAR-expressing T cells to patients is a promising approach for cancer 
immunotherapy [107–109,120].  Despite these encouraging results, safety and efficacy 
continue to be major hurdles that hinder CAR T cell therapy development 
[60,110,121,122].  To improve overall effectiveness and safety of CAR T cell therapy, 
there is an urgent need for a better system that can finely tune T cell activation, enhance 
tumor specificity, and independently control different signaling pathways and cell types. 
The CAR T cells used in clinical trials typically have a rigid design that is difficult to 
alter without re-engineering the T cells.  Current CAR designs are composed of a fixed 
antigen-specific single-chain variable fragment (scFv) and intracellular signaling domains 
(CD3 and co-stimulatory domains).  When the constant antigen-specific CAR binds to the 
target antigen, these invariable signaling domains are activated simultaneously at a 
predetermined level. Due to the fixed design that limited the controllability of CAR T cell 
activation level, managing CAR T cell-related toxicities have proven to be challenging 
[58,107,110]. 
In addition to constraining the controllability of CAR T cell activity, this fixed CAR 
design also restricts the antigen specificity and affinity. High-affinity scFvs are often used 
in the CAR design to ensure high antigen specificity. However, CARs made with high-
affinity scFvs have limited capacity in discriminating antigen density, which have led to 
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dangerous reactivity against healthy organs expressing a low level of antigens [59,60].  
Using an scFv with lower antigen affinity allowed better antigen density discrimination 
[123,124], but antigen specificity may be compromised. Thus, modulation of CAR 
components other than scFv affinity may be needed for improving CAR T cell specificity. 
Recently, several studies have demonstrated the importance of regulating CD3 and 
the different co-stimulatory pathways independently to achieve optimal T cell response 
[62,125,126]. Also, the activation of different co-stimulatory domains (e.g., CD28 or 4-
1BB) is known to have different T cell functions and phenotypes (e.g., T cell differentiation 
and memory T cell formation) [127–129], demonstrating the value of CAR design that 
allows independent control of different signaling domains.  
The composition of the T cell subsets, such as the ratio of CD4+ and CD8+ T cells, has 
also been shown to be an important parameter for enhancing the antitumor response of 
CAR T cells [130].  Given the fact that our immune system is composed of many different 
T cell subtypes with distinct effector functions (Golubovskaya and Wu, 2016; Vignali et 
al., 2008; Vivier et al., 2008), regulating the activity of T cell subtypes independently may 
be an attractive strategy for optimizing the efficacy of CAR T cell therapy [131]. However, 
current fixed CAR design limits independent and inducible activation of different signaling 
domains or different T cell subsets to achieve user-defined diverse T cell response.  
New receptor designs have been developed to address some of the deficiencies (e.g., 
controllability, flexibility, and specificity) in current CAR T cell therapies. For instance, 
drug-inducible ON and kill switches have been developed to regulate CAR activity [15,83]. 
Also, to afford greater flexibility in antigen recognition, CARs have been split such that 
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the antigen recognition motif is dissociated from the signaling motif of the CAR. This split 
CAR configuration uses a universal receptor as the common basis for all interactions, 
allowing a large panel of antigens to be targeted without re-engineering the immune cells 
[78,80,81,132]. In addition, to increase tumor specificity, CARs were developed that allow 
combinatorial antigen sensing [62,63,126] or target two tumor-specific antigens that can 
reduce tumor antigen escape rate [65,76]. All of these features are arguably vital to ensure 
a safe and effective CAR T therapy. However, none of these advanced CARs has 
incorporated all of these features into one system. Additionally, the signaling pathways and 
cell types that can be activated are also fixed, thus limiting the diverse immune responses 
that can be achieved. 
To enhance the specificity, safety, and programmability of CARs, we develop a split, 
universal, and programmable (SUPRA) CAR system composed of a universal receptor 
expressed on T cells and a tumor-targeting scFv adaptor molecule (Figure 3.6.1A).  The 
activity of SUPRA CARs can be finely regulated via multiple mechanisms to limit 
overactivation.  SUPRA CARs can also logically respond to multiple antigens for 
improving tumor specificity.  We show the SUPRA CAR system is effective against two 
different tumor models, demonstrating the broad clinical potential of this system.  In 
addition, we show that SUPRA components can be humanized to reduce potential 
immunogenicity.  Furthermore, we use orthogonal SUPRA CARs to inducibly regulate 
multiple signaling pathways or different human T cell subtypes to increase the range of the 
immune responses that can be achieved.  Together, the SUPRA CAR system is a feature-
rich system with inducible and logical control capabilities that can improve the safety and 
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efficacy of current cellular cancer immunotherapy. 
 
3.2 Results 
 
3.2.1 Design and characterization of the SUPRA CAR system 
 
The SUPRA CAR is a two-component receptor system composed of a universal 
receptor (zipCAR) expressed on T cells and a tumor-targeting scFv adaptor (zipFv) 
(Figure 3.6.1A).  The zipCAR universal receptor is generated from the fusion of 
intracellular signaling domains and a leucine zipper as the extracellular domain. The zipFv 
adaptor molecule is generated from the fusion of a cognate leucine zipper and an scFv. The 
scFv of the zipFv binds to the tumor antigen, and the leucine zipper binds and activates the 
zipCAR on the T cells (Figures 3.6.8A and 3.6.9). Unlike the conventional fixed CAR 
design, the SUPRA CAR modular design allows targeting of multiple antigens without 
further genetic manipulations of a patient’s immune cells (Figure 3.6.1B, left). To test the 
ability of the SUPRA CAR system targeting multiple antigens with the same batch of T 
cells expressing the zipCAR, we first engineered human primary CD8+ T cells to express 
an RR zipCAR (RR leucine zipper with CD28, 4-1BB co-stimulatory and a CD3 signaling 
domain, Figure 3.6.8A). Next, we designed three different zipFvs to target three common 
tumor antigens (α-Her2, α-Axl, and α-Mesothelin, Figure 3.6.8A) by fusing the 
corresponding scFvs to an EE leucine zipper, which binds to the RR zipCAR on T cells.  
The engineered CD8+ T cells were co-cultured in vitro with K562 myelogenous leukemia 
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cells that express Her2, Axl, or Mesothelin tumor antigens. The CD8+ zipCAR T cells 
killed the corresponding tumor cells when the matching zipFvs were added (Figure 3.6.1B, 
right).  
A unique feature of the split CAR design is that it has multiple tunable variables, 
such as (1) the affinity between leucine zipper pairs, (2) the affinity between tumor antigen 
and scFv, (3) the concentration of zipFv, and (4) the expression level of zipCAR, that can 
be used to modulate the T cell response (Figure 3.6.1C).  We first characterized the effect 
of zipFv concentration and zipper affinity on T cell activation.  We generated three zipFvs 
with the same -Her2 scFv but fused to leucine zippers (SYN5, SYN 3, and EE) that have 
different affinity to the RR zipCAR  [133,134].  The amount of zipFv required to activate 
T cells to half-maximal IFN-γ secretion and cytotoxicity inversely correlated with the 
affinity of leucine zipper pairs where -Her2-EE zipFv showed the lowest EC50 and -
Her2-SYN5 zipFv showed the highest EC50 value (Figures 3.6.1D and 3.6.8C).  Also, the 
maximum level of IFN-γ secretion or killing efficiency correlated with the affinity of 
leucine zipper pairs. 
We next investigated the effect of scFv–tumor antigen affinity, leucine zipper 
affinity, and zipCAR expression levels on the IFN-γ secretion and cancer-killing efficiency 
by the SUPRA CAR T cells (Figures 3.6.1E and 3.6.8D).  We created 12 different zipFvs 
(three different leucine zippers with different affinity and four scFvs against Her2 (G98, 
C65, ML39, and H3B1) with Kd ranging from 3.2 x 10
-7 to 1.2 x 10-10 M) [135].  We also 
generated two batches of T cells with high or low RR zipCAR expression level using 
fluorescence-activated cell sorting (Figure 3.6.8B).  Cells expressing higher levels of 
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zipCAR exhibited greater cytokine secretion when activated (Figure 3.6.1E). The affinity 
of scFv to Her2 correlated weakly with cytokine secretion or target cell lysis [135].  The 
affinity between leucine zippers, however, correlated well with cellular activation 
regarding cancer cell killing efficiency and cytokine secretion. As high-affinity scFv CARs 
often over-activate and show severe toxicities in clinical trials [58,59], the SUPRA 
platform can mitigate these toxicities by controlling other factors (e.g., zipFv 
concentration, the affinity between leucine zipper pairs) to regulate T cell activation level. 
Together, these results demonstrate the tunable and modular nature of the SUPRA CAR 
design. 
 
3.2.2 Competitive zipFvs for tuning SUPRA CAR activity 
 
As many patients treated with CAR T cell therapy face cytokine release syndrome 
which can be life-threatening [57,60], it is important to prevent CAR T cell activity when 
necessary. Thus, we explored the possibility of inhibiting the SUPRA CAR T cell 
activation through the addition of a competitive zipFv that can bind to the other zipFv, thus 
preventing zipCAR from being activated (Figure 3.6.2A, left). To test this approach, we 
screened several competitive zipFvs with different affinities for the EE zipFv (strong, 
medium and weak) (Figures 3.6.10B and 3.6.10C). Human CD8+ T cells were transduced 
with RR zipCAR and co-cultured with Her2+ K562 cells. Then EE zipFv (22.5nM, red) 
was subsequently added to activate the T cells.  Without the competitive zipFv, the EE 
zipFv alone could activate T cells to destroy Her2+ cancer cells (Figure 3.6.2A, right). 
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However, when the competitive zipFv (SYN4, SYN 47, or SYN 13) was also introduced 
(90nM, green), it bound to the EE zipFv and prevented the EE zipFv from activating the 
zipCAR T cells.  By utilizing this competitive approach, we were able to inhibit primary 
CD8+ T cell activation in vitro with the strong competitive zipFv (SYN4). Furthermore, 
we were able to tune the activation levels with weaker binding zippers (SYN 47 and SYN 
13). To understand inhibition dynamics, we varied the amount of competitive zipFv and 
timing of its addition. The increasing amount of competitive zipFv or delaying competitive 
zipFv addition did not affect inhibition strength greatly (Figure 3.6.10D).   
 
3.2.3 Logical operation with the SUPRA CAR system 
 
Antigen escape is a major challenge for targeted cancer therapies [136], including 
adoptive T cell therapies [75,137]. As such, bispecific receptors that can be triggered by 
CD19 and Her2 or CD19 and CD20, respectively, have been developed to combat antigen 
escape [65,76]. Also, CD22 and CD123 CARs have been recently developed to increase 
tumor specificity [67,138]. However, as illustrated in a recent clinical trial with CD22 CAR 
T cells for patients relapsed from CD19 CAR T therapy, tumors can still evade detection 
by the engineered T cells by losing or down-regulating both antigens [66].  In such cases, 
T cells would need to be re-engineered to target another antigen.  Using the SUPRA CAR 
platform, however, different antigens can be easily targeted without further genetic 
manipulation. To test if SUPRA CAR could be used to target either one of the two antigens 
on the cell surface, we co-cultured Her2/Axl+ K562 cancer cells with RR zipCAR 
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expressing CD8+ T cells. Then, different zipFv combinations were added to the cell 
mixture (α-Axl zipFv, α-Her2 zipFv, or both) (Figure 3.6.2B). As expected, the addition 
of zipFv targeting either Her2, Axl or both led to high killing efficiency, illustrating the 
potential of programming the SUPRA CAR system to combat antigen escape. 
Another limitation of targeted tumor therapy is the difficulty in identifying a single 
tumor-specific antigen, which affects both tumor specificity and toxicity. Receptor systems 
that can perform combinatorial antigen detection have been developed to enhance the 
specificity of CAR T cell therapy [62,63].  However, these receptor systems have a fixed 
antigen specificity design.  Here, we investigated if the SUPRA CAR system can also be 
used to increase tumor specificity through combinatorial antigen sensing (Figure 3.6.2C).  
In particular, we used the SUPRA CAR system to target cells that express Her2 only and 
spare cells that express both Her2 and Axl, where Axl served as a “safety marker”. To 
achieve our design, we developed an α-Axl-SYN2 zipFv (green) that binds to α-Her2-EE 
zipFv (red) through a complementary zipper on each zipFv; this prevents the α-Her2-EE 
zipFv from binding to the zipCAR, thus protecting the Her2+/Axl+ cells.  In contrast, since 
-Axl-SYN2 zipFv cannot bind to Her2-only cells, the α-Her2-EE zipFv will not be 
blocked from activating the zipCAR.  
To demonstrate such Her2 but NOT Axl logical operation, we first co-cultured RR 
zipCAR expressing CD8+ T cells with Her2+/Axl+ cells and zipFvs (Figure 3.6.2C, left).  
As expected, the addition of the α-Her2-EE zipFv alone achieved high tumor killing 
efficiency. However, when the α-Her2-EE zipFv was added after the α-Axl-SYN2 zipFv, 
the two zipFvs bound to each other and prevented the activation of the zipCAR, which led 
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to a significant reduction in cytotoxicity (Figure 3.6.2C, right). As a control, we designed 
an α-Axl-SYN13 zipFv that did not bind strongly to the α-Her2-EE zipFv and showed no 
inhibition of T cell activity (Figure 3.6.10E). When the same SUPRA CAR system was 
challenged equally with cells expressing only Her2, the presence of α-Her2-EE zipFv alone 
again showed a high cytotoxicity rate (Figure 3.6.2C, right).  Moreover, the addition of 
α-Axl zipFvs did not affect killing efficiency. For both dual and single antigen target cells, 
α-Axl-SYN2 zipFv that binds strongly to α-Her2-EE zipFv or α-Axl-SYN13 zipFv that 
does not bind strongly to α-Her2-EE zipFv was first added to the cell mixture. After 
unbound α-Axl zipFvs were washed away, α-Her2-EE zipFv was added to stimulate CD8+ 
T cell activity (refer to the STAR Method section for further detail). As expected, RR 
zipCAR engineered CD8+ T cells showed high activity toward Her2+ cancer cells, 
regardless of zipFv combinations, thus demonstrating the potential of the SUPRA CAR 
system to increase tumor specificity and reduce the toxicity of CAR T cell therapy.  
 
 
 
3.2.4 Tumor clearance in a xenograft tumor model 
 
After characterizing the SUPRA CAR system in vitro, we next tested whether 
SUPRA CARs can be used to reduce the tumor burden in a mouse xenograft model.  For 
this experiment, we injected SK-BR-3 breast cancer cells (Her2 positive) intraperitoneally 
into immunocompromised NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice.  After two weeks 
to allow for tumor establishment, we injected primary CD8+ human T cells expressing RR 
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zipCAR or conventional Her2 CAR into the mice. α-Her2-EE zipFv was subsequently 
injected every 2 days at 5mg/kg for 2 weeks. Tumor growth was monitored by in vivo 
imaging (IVIS) of the luciferase signal from SK-BR-3 cancer cells in each mouse over the 
course of 41 days.  RR zipCAR with α-Her2-EE zipFv showed robust tumor burden 
clearance, comparable to the conventional Her2 CAR.  However, T cells expressing RR 
zipCAR alone without zipFvs were not able to reduce tumor burden (Figure 3.6.3A).  
To verify that the decrease in tumor burden was due to binding between zipCAR 
and zipFv, we also tested an -Her2-RR zipFv, which does not bind to the RR zipCAR 
(Figures 3.6.3B and 3.6.11A). We set up a similar tumor model with SK-BR-3 breast 
cancer cells and injected RR zipCAR expressing CD8+ T cells at day 38 (Figures 3.6.11A 
and 3.6.11B). Both zipFvs (-Her2-RR or -Her2-EE) were dosed every two days for two 
weeks at 8mg/kg.  Representative IVIS images and quantified luminescence from each 
mouse at day 57 demonstrated a decrease in tumor burden only when the -Her2-EE zipFv 
that binds to zipCAR was injected (Figure 3.6.3B and 3.6.3C).  We also measured the 
cytokine release in vivo to verify that cytokine production is specific to the binding between 
zipFv and zipCAR.  As expected, the injection of  -Her2-RR zipFv did not increase IFN-
 level in vivo.  However, the administration of the -Her2-EE zipFv showed a significant 
increase in IFN- after 24 hours of CD8+ T cells and zipFv injection (Figure 3.6.3D). 
Intraperitoneal xenograft tumor models are frequently used to evaluate 
immunotherapy against human ovarian cancers [139–142], but demonstrating the efficacy 
of the SUPRA system with a blood tumor model could further validate the applicability of 
this system against different tumors (e.g., T cell cancers).  As such, we also tested the 
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SUPRA system against a blood tumor model.  We injected modified Jurkat T cancer cells 
(engineered to be Her2 positive) intravenously into immunocompromised NSG mice.  
After three days, we injected primary CD8+ human T cells expressing RR zipCAR or 
conventional Her2 CAR into the mice. α-Her2-EE zipFv was subsequently injected every 
day at 3mg/kg for six days. Tumor growth was monitored by in vivo imaging (IVIS) of the 
luciferase signal from Jurkat cancer cells in each mouse over the course of 21 days.  RR 
zipCAR with α-Her2-EE zipFv showed robust tumor burden clearance, comparable to the 
conventional Her2 CAR.  However, T cells expressing RR zipCAR alone without zipFvs 
were not able to reduce tumor burden (Figure 3.6.3E). Moreover, the long-term survival 
rate was observed for the group that received both RR zipCAR with α-Her2-EE zipFv 
(Figure 3.6.12A). We further characterized our SUPRA CAR system in this blood tumor 
model by modulating T cell numbers (from 10x106 per mice to 2.5x106 per mice) and 
lowering zipFv dose to 1mg/kg (Figures 3.6.12B and 3.6.12C). At these reduced T cell 
numbers and zipFv doses, robust reduction of tumor burden was still observed. The 
observed robust activity of the SUPRA system against different xenograft tumor models 
demonstrates the potential of the SUPRA CAR system to combat many different cancers. 
 
3.2.5 Characterization of the humanized SUPRA CAR system in vitro and in vivo 
 
To mitigate the potential immunogenicity against synthetic leucine zippers, we 
created a new zipCAR and zipFv pair using zipper domains derived from human FOS and 
JUN transcription factors, respectively [133,143]. Human primary CD8+ T cells were 
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engineered to express a FOS zipCAR.  An α-Her2-JUN zipFv was used to activate the FOS 
zipCAR (Figure 3.6.13A). FOS zipCAR and RR zipCAR engineered CD8+ T cells have 
comparable in vivo killing efficiencies against Jurkat T cells that express Her2 (Figure 
3.6.13A).  In addition, FOS zipCAR can be activated only when α-Her2-JUN zipFv and 
Her2 expressing tumor cells are present as measured by CD69 expression and IFN- 
secretion (Figures 3.6.13B and 3.6.13C). FOS zipCAR with α-Her2-JUN zipFv can 
efficiently eliminate leukemia in vivo as demonstrated in a blood tumor model (Figure 
3.6.13D).  Together, these results illustrate that the SUPRA components can be humanized 
to reduce potential immunogenicity and they are as effective as the ones derived from 
synthetic zippers. 
 
3.2.6 Controlling SUPRA CAR activity in vivo 
 
Strategies that enable controlled cytokine production by CAR T cells in vivo are 
critical to preventing cytokine release syndrome [57,60].  As such, we explored in vivo 
cytokine production by SUPRA CAR T cells in a zipFv dose-dependent manner.  We first 
injected SK-BR-3 breast cancer cells and allowed the tumor to be established (Figure 
3.6.4C).  After verifying tumor establishment, RR-zipCAR expressing CD8+ T cells were 
injected and mice were dosed with 8, 4, 2, or 0.5 mg/kg of the α-Her2-EE zipFv every other 
day for 2 weeks (Figure 3.6.11BC).  Again, the tumor burden was monitored by in vivo 
imaging (IVIS) of the luciferase signal from SK-BR-3 cancer cells in each mouse.  
Increasing zipFv dose beyond 2mg/kg (e.g., 4mg/kg or 8mg/kg) resulted in the faster and 
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more efficient killing of cancer cells. There were no significant differences between groups 
that received 0.5mg/kg and 2mg/kg or between groups that received 4mg/kg and 8mg/kg 
(Figure 3.6.11D). However, zipFv dosage correlated with cytokine release in vivo in a 
step-wise fashion, which demonstrates the possibility of using the SUPRA CAR to finely 
regulate cytokine release in vivo (Figure 3.6.4A). 
We also examined if in vivo cytokine production could be modulated with different 
leucine zippers (SYN3, SYN5, and EE) or -Her scFv (G98, ML39, and H3B1) affinity 
on the zipFv (4mg/kg) (Figures 3.6.4B and 3.6.11E).  Indeed, in vivo IFN- release 
correlated with the affinity between leucine zippers (Figure 3.6.4B).  The cytokine release 
also increased as the scFv changed from low (G98, Kd = 3.2 X 10
-7) to medium-high affinity 
(ML39, H3B1, Kd < 1 X 10
-8).  However, as shown in the in vitro results, zipFvs with 
medium-high binding domains affinity (ML39, H3B1, Kd < 1 X 10
-8) did not increase IFN-
 secretion (Figures 3.6.11E).  
Lastly, we investigated if the SUPRA CAR could be inhibited in vivo with a 
competitive zipFv to reduce cytokine production (Figures 3.6.4C).  As expected, the group 
that only received α-Her2-EE zipFv (4mg/kg) secreted a high level of IFN-. Moreover, 
when a competitive zipFv (8mg/kg) that can bind to the activating zipFv was added 
(SYN4), the IFN- level reduced significantly, similar to that of the no-zipFv control.  
However, the addition of a control zipFv, which does not bind to the activating EE zipFv, 
did not decrease cytokine release in vivo (SYN13).  We did not observe a significant effect 
of competitive zipFvs on the anti-tumor cytotoxicity in vivo. However, in vivo cytokine 
production results demonstrate that the SUPRA CAR platform affords multiple approaches 
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to control cytokine production, providing the tools needed to manage severe cytokine 
release syndrome and other potential toxicities that arise from conventional CAR T cell 
therapies.  
 
3.2.7 Controlling different signaling domains using orthogonal SUPRA CARs 
 
Currently, only a small number of signaling domains are being utilized in CAR T 
cell therapy to regulate T cell responses. Moreover, we lack independent control of 
different signaling domains as they are activated simultaneously.  However, the repertoire 
of co-signaling domains  both co-stimulatory and co-inhibitory domains  are highly 
diverse, and it is the activation of different co-signaling domains that sculpts ultimate T 
cell function [144–146]. One of the key attributes of the SUPRA CAR design is that 
multiple orthogonal SUPRA CARs can be designed to control distinct signaling pathways 
in the same cell, which provides highly customizable tuning of T cell signaling and 
response.  To identify orthogonal SUPRA CARs, Jurkat T cells expressing different 
zipCARs were co-cultured with Her2+ K562 target cells and different zipFvs. (Figures 
3.6.13A and 3.6.13B).  From the screen, we identified several pairs of orthogonal SUPRA 
CARs (Figures 3.6.13C). We then engineered two orthogonal SUPRA CARs to regulate 
separate signaling pathways in primary CD4+ T cells  FOS zipCAR (binds to α-Her2-
SYN9 zipFv) that contains only a CD3 domain and RR zipCAR (binds to α-Axl-EE 
zipFv) that contains CD28 and 4-1BB co-stimulatory domains (Figures 3.6.5A).  We chose 
these signaling domains because they have been used previously for demonstrating 
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combinatorial antigen detection (“AND” logic) in vivo [62].  To trigger each zipCAR 
independently, we co-cultured engineered CD4+ T cells and K562 target cells that express 
Her2 and Axl.  We then added two different zipFvs at varying concentrations and measured 
CD69 expression, which can be triggered by CD28 activation [147].  Triggering CD3 
alone increased CD69 expression. Activating the CD28/4-1BB and CD3 domain, 
however, led to a further increase in CD69 expression (Figures 3.6.5B and 3.6.14F). To 
confirm this dual antigen sensing functionality, we also measured different cytokine (IFN-
, IL-2, and IL-4) levels that are known to be regulated by CD28 and 4-1BB signaling 
[148–150].  For all cytokines tested, we observed similar synergistic AND logic effects of 
these two receptors (Figures 3.6.5B, 3.6.14D, 3.6.14E, and 3.6.14F). Surprisingly, the 
effect of the CD28 and 4-1BB co-stimulatory signaling was much higher when we 
increased the α-Her2-SYN9 zipFv concentration (as CD3 signaling strength increased) 
(Figures 3.6.14F).  
 
3.2.8 Controlling different cell types using orthogonal SUPRA CARs 
 
We recognized that orthogonal SUPRA CARs can also be used to control different T 
cell subtypes, such as CD4+ and CD8+ T cells (Figures 3.6.6A).  CD4+ T cells are helper 
T cells that secrete a variety of cytokines and regulate the immune responses such as 
activation, growth, and memory formation of CD8+ T cells [151].  CD8+ T cells are 
cytotoxic T cells that can directly kill cancer cells. As the use of both CD4+ and CD8+ T 
cells has been shown to enhance the antitumor response of CAR T cells [130], independent 
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control of both cell types to induce different T cell responses could further improve the 
effectiveness of CAR T cell therapy. To demonstrate orthogonal control of both T cell 
types, we introduced an RR zipCAR into CD4+ T cells (binds to α-Axl-EE zipFv) and an 
orthogonal FOS zipCAR (binds to the α-Her2-SYN9 zipFv) into CD8+ T cells.  All 
zipCARs here contain CD3, CD28, and 4-1BB signaling domains.  To trigger each cell 
type independently, we co-cultured both engineered CD4+ and CD8+ T cells with K562 
cells that express Axl and Her2 (Figures 3.6.6A).  CD69 expression level was upregulated 
in CD4+ or CD8+ T cells only in response to the addition of α-Axl zipFv or α-Her2 zipFv, 
respectively.  When both zipFvs were added simultaneously, the CD69 level was 
upregulated for both cell types (Figures 3.6.6B).  Furthermore, activating both cell types 
simultaneously achieved IFN- secretion levels similar to the sum of cytokine secretion 
levels from two subsets of T cells activated individually (Figures 3.6.6C). Finally, 24-hour 
co-culture of CD4+ and CD8+ T cells with Axl+/Her2+ K562 cells led to cytotoxicity 
against tumor cells (as measured by K562 population percentage through flow cytometry) 
when CD8+ T cells were activated, but minimally for CD4+ T cells [152] (Figures 3.6.6D). 
 
 
3.3 Discussion 
3.3.1 SUPRA CAR: The Swiss Army knife of CAR 
 
There is a great need for a flexible platform that can control T cell activation with 
improved precision and tunability to make CAR T cell therapy safer and more effective.  
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Here we have developed a split CAR system with enhanced flexibility, specificity, and 
controllability.  We demonstrated that our SUPRA CAR system can target different 
antigens without having to re-engineer the T cells.  The activity of the SUPRA CAR system 
can also be flexibly modulated through multiple mechanisms.  In addition, the SUPRA 
CAR can be easily designed for combinatorial logic antigen detection and regulate different 
signaling pathways in the same cell as well as different cell types independently.  Together, 
the SUPRA CAR represents a feature-rich receptor system for adoptive T cell therapy. 
While several split systems have been introduced with biomolecule-labeled 
antibodies [78–81,153] to redirect the specificity of CARs, none of these systems have 
demonstrated the same level of flexibility and functionality as our SUPRA CAR system.  
Furthermore, some of the systems require extensive and non-intuitive optimization of the 
receptor design.  The modular design approach of our SUPRA CAR platform, however, 
allows convenient redirection of target specificity and adjustment to T cell activity. Several 
structural parameters, such as the location of the scFv binding to the antigen, scFv affinity, 
and extracellular spacing [65,78,154] are important to the CAR signaling.  Given that the 
leucine zipper design constraints some of the structure parameters (e.g. the extracellular 
spacing) of the zipCAR, further investigation would be needed to determine the effect of 
these parameters on the SUPRA CAR system activity.  
We were able to generate zipFvs targeting three different targets without having to 
individually optimize each zipFv. Moreover, we showed that SUPRA CAR components 
can be humanized by using leucine zipper domains derived from human transcription 
factors to reduce potential immunogenicity. Because these endogenous leucine zippers are 
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localized inside the cells, we do not expect crosstalk to occur between humanized SUPRA 
CAR components and human transcription factors.  In addition, although not investigated 
here, we anticipate that each zipFv will have a short pharmacokinetic half-life in vivo, 
similar to an scFv [155], which could allow increased temporal control, and we expect that 
its small size will lead to increased tumor penetration [156]. However, the short serum half-
life could also be problematic as the SUPRA system requires zipFvs to maintain in vivo T 
cell activity. Nonetheless, SUPRA CAR T cells were able to clear tumor burden in vivo 
with a zipFv dose comparable to other FDA approved protein drugs.  Moreover, several 
well-developed protein engineering approaches are available (e.g., PEGylation, 
Fc/Albumin fusion, Glyco-engineering) to increase the half-life of scFv, which can be 
employed to modulate zipFv stability in vivo if necessary [157–160].  
 
3.3.2 SUPRA CAR could enhance the safety of T cell therapy 
 
Controlling cytokine secretion is critical to limiting cytokine release syndrome in 
patients.  We were able to titrate cytokine secretion and cytotoxicity with different zipFv 
doses and configurations, demonstrating the tunability of the SUPRA system in vivo.  
Furthermore, we showed through the use of competitive leucine zippers for OFF switch 
function, that one can significantly reduce cytokine secretion both in vitro and in vivo.  
Moreover, this competition-based strategy can improve target specificity by directing the 
competitive zipFv toward a surface marker for “normal” cells, thus safeguarding them from 
being targeted by the zipCAR.  We anticipate that to efficiently block the accessibility of 
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zipCAR, the expression level of the cancer cell marker and the normal cell marker will 
need to be comparable. 
 
3.3.3 Toward the synthesis of a prosthetic immune system   
 
A central feature of the SUPRA CAR system is the availability of orthogonal 
zippers with the varying affinity [133], thus providing a valuable resource for engineering 
facile and complex control of T cell signaling.  Most CARs have been designed as a single 
receptor controlling all the necessary signaling domains at the same time at a preset (but 
undefined) level.  In contrast, we have shown that multiple orthogonal SUPRA CARs can 
be utilized to control different signaling domains (e.g., CD3, CD28, 4-1BB), which enable 
independent and tunable control of different signaling pathways.  Moreover, each CAR can 
be paired with zipFvs that target different tumor antigens or with a different affinity of the 
leucine zipper, thus allowing regulatable combinatorial antigen sensing, a useful feature 
that has not been achieved in other CAR or receptor systems (Figures 3.6.7A).  
Furthermore, previous designs for combinatorial antigen sensing using two CARs often 
require precise control of the expression level of each receptor or careful choice of scFv 
affinity to achieve an optimal balance of signaling strength [62].  While useful and novel, 
such designs lack the flexibility to combat tumor relapse due to antigen escape, which will 
require the extensive design of a different dual CAR system.  However, with the SUPRA 
system, the zipFv composition can be simply changed and the signaling strength from each 
receptor can be easily tuned by the amount of zipFv, rather than re-engineering T cells,  to 
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meet the challenge of antigen escape.    
In addition to regulating different signaling pathways, multiple orthogonal SUPRA 
CAR can also be used to control different subsets of immune cells.  Current CAR-based 
therapy is typically implemented in a cell mixture (e.g., peripheral blood mononuclear 
cells) or single subsets of immune cell types (e.g., CD4+, CD8+, Treg, or NK cells [161–
164]).  Even when two defined T cell subsets (CD4+ and CD8+) were utilized, they were 
not regulated independently.  Given that our immune system is composed of many different 
cell types with unique effector functions and behaviors in vivo, a platform that enables 
independent control of different cell types could greatly increase the range of responses 
that can be achieved by the engineered cells (Figures 3.6.7B).  As a proof of concept, we 
engineered two different T cells subtypes (CD4+ and CD8+) and demonstrated that two 
orthogonal SUPRA receptors can independently regulate two cell types.  While it is 
possible to engineer two cell types with conventional fixed CARs that target different 
antigens, our SUPRA system enables the first orthogonal inducible control of two cell types 
simultaneously.  We anticipate that the SUPRA system can also be applied to regulatory T 
cells and NK cells along with CD4+ and CD8+ T cells to form a prosthetic immune system 
that allows unparalleled control for cell-based immunotherapy (Figures 3.6.7B).  
 
 
3.4 Conclusion 
 
T cells expressing chimeric antigen receptors (CARs) are promising cancer therapeutic 
agents, with the prospect of becoming the ultimate smart cancer therapeutics. To expand 
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the capability of CAR T cells, here we present a split, universal, and programmable 
(SUPRA) CAR system that simultaneously encompasses multiple critical “upgrades”, such 
as the ability to switch targets without re-engineering the T cells, finely tune T cell 
activation strength, and sense and logically respond to multiple antigens.  These features 
are useful to combat relapse, mitigate over-activation, and enhance specificity.  We test our 
SUPRA system against two different tumor models to demonstrate its broad utility and 
humanize its components to minimize potential immunogenicity concerns.  Furthermore, 
we extend the orthogonal SUPRA CAR system to regulate different T cell subsets 
independently, demonstrating a dually inducible CAR system. Together, these SUPRA 
CARs illustrate that multiple advanced logic and control features can be implemented into 
a single, integrated system. 
 
 
 
3.5 Methods 
3.5.1 zipCAR Receptor Construct Design 
zipCARs were designed by fusing different leucine zippers [133,134] to the hinge 
region of the human CD8α chain and transmembrane and cytoplasmic regions of the human 
CD28, 4-1BB, and CD3 signaling endodomains. They were under SFFV promoter for all 
primary T cell experiments and under CAG promoter for all Jurkat cell experiments. All 
zipCARs contain myc tag to verify surface expression. Furthermore, zipCARs used in 
primary T cell experiments were fused to mCherry after CD3 chain to visualize 
expression. ZipCARs used in Jurkat experiments were cloned into the piggyback vector 
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(System Bioscience Inc.), which has been modified by replacing CMV promoter to CAG 
promoter. 
3.5.2 ZipFv Construct Design 
The general design of zipFv is as follows. scFv (α-HER2, α-Axl or α-MESO) is 
linked by a 35-aa glycine/serine linker to a leucine zipper. Constructs were cloned into 
pSecTag2A vectors (Thermo Fisher) for transient expression. These vectors contain the 
CMV promoter, murine Ig-k-chain leader sequence, C-terminal c-myc epitope, and a 6X 
His tag for purification. 
 
3.5.3 Expression and Purification of zipFv 
For transient expression of the protein, Freestyle 293-F cells (Thermo Scientific 
#R79007) were transfected with pSecTag2A plasmid according to the supplier’s protocol. 
After 4 days of culture, cells were pelleted by centrifugation at 300 × g for 5 minutes, and 
supernatant protein expression was confirmed by Coomassie gel stain (Thermo Scientific 
#24592) and western blot (Abcam #ab62928). Proteins derived from transient transfection 
were purified as follows. The supernatant was passed through columns containing ProBond 
nickel chelating resin (Thermo Scientific #R80101). Then, each column was washed four 
times with native purification buffer (50 mM NaH2PO4 and 0.5 M NaCl pH 8.0) plus 20 
mM imidazole (Sigma Aldrich # I5513) and eluted three times with native purification 
buffer plus 250mM imidazole concentrations. Eluted proteins were concentrated to ~2ml 
and dialyzed into 1× PBS (Thermo Scientific #AM9625). After dialysis, the protein was 
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verified by western blot and SDS-PAGE gel electrophoresis and protein concentration was 
quantified by the Pierce BCA Protein Assay Kit (Thermo Scientific # 23227). 
 
3.5.4 Western Blot and SDS-PAGE Gel Electrophoresis 
SDS-PAGE gel electrophoresis was performed via a standard protocol. Briefly, 
protein samples were mixed with NuPAGE LDS sample buffer (Thermo Scientific 
#NP0008) and NuPAGE reducing agent (Thermo Scientific). Samples were heated at 90ºC 
for 20 minutes and run in NuPAGE MOPS SDS running buffer (Thermo Scientific 
#NP0001). SDS-PAGE gel was stained with GelCode Blue stain (Thermo Scientific 
#24590) and images were taken using Gel Doc EZ imager (Biorad). Western blot was 
performed using iBlot2 gel transfer device (Thermo Scientific #NP0009), following the 
manufacturer's protocol. For detection, α-C-Myc-HRP antibody (Abcam #ab62928) was 
used.  
 
3.5.5 Primary Human T cells Isolation and Culture 
Normal whole peripheral blood was obtained from Boston Children’s hospital, as 
approved by the University Institutional Review Board (IRB) approved consent forms and 
protocols. Primary human CD4+ and CD8+ T cells were isolated from anonymous healthy 
donor blood by negative selection (STEMCELL Technologies #15062 and #15063). T cells 
were cultured in human T cell medium consisting of X-Vivo 15 (Lonza), 5% Human AB 
serum (Valley Biomedical #HP1022), 10 mM N-acetyl L-Cysteine (Sigma-Aldrich 
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#A9165), 55uM 2-mercaptoethanol (Thermo Scientific #31350010) supplemented with 50 
units/mL IL-2 (NCI BRB Preclinical Repository). T cells were cryopreserved in 90% heat-
inactivated FBS and 10% DMSO.  
 
3.5.6 Lentiviral Transduction of Human T cells 
Replication-incomplete lentivirus was packaged via transfection of HEK 293 FT 
cells (Invitrogen) with a pHR transgene expression vector and the viral packaging 
plasmids: pMD2.G encoding for VSV-G pseudotyping coat protein (Addgene #12259), 
pDelta 8.74 (Addgene#22036), and pAdv (Promega). One day after transfection, viral 
supernatant was harvested every day for 3 days and replenished with pre-warmed 
Ultraculture media (Lonza #12-725F) with 2mM L-glutamine, 100U/ml penicillin, 
100ug/mL streptomycin, 1mM sodium pyruvate, and 5mM sodium butyrate. Then, the 
harvested virus was purified through ultracentrifugation or Lentivirus concentrator (Takara 
#631232). Primary T cells were thawed 2 days before ultracentrifugation and cultured in T 
cell medium described above. One day before ultracentrifugation, T cells were stimulated 
with Human T-activator CD3/CD28 Dynabeads (Thermo Scientific #11132D) at a 1:3 
cell:bead ratio and cultured for 24 hr. After viral supernatant purification, rectronectin 
(Clontech #T100B) was used to transduce cells. Briefly, non-TC treated 6-well plates were 
coated with rectronectin following the supplier’s protocol. Then, concentrated viral 
supernatant was added to each well and spun for 90 min at 1200xg. After centrifugation, 
viral supernatant was removed and 4ml of human T cells at 250k/ml in T cell growth media 
supplemented with 100U/ml of IL-2 was added to well. Cells were spun at 1200xg for 60 
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min and moved to an incubator at 37 ºC.   
3.5.7 Cancer Cell Lines 
The cancer cell lines used were K562 myelogenous leukemia cells (ATCC # CCL-
243), Jurkat T cells, and SK-BR-3 (ATCC #HTB-30). K562 and Jurkat cells were cultured 
in RPMI-1640(Lonza#12-702Q) with 5% (v/v) heat-inactivated FBS, 2mM L-glutamine, 
100U/ml penicillin and 100ug/mL streptomycin. SK-BR-3 cells were cultured in 
DMEM(Corning #10-013) supplemented with 10% (v/v) heat-inactivated FBS, 2mM L-
glutamine, 100U/ml penicillin and 100ug/mL streptomycin. Jurkat, K562, and SK-BR-3 
were electroporated or transfected with PiggyBac Transposon system (System 
Biosciences) to stably express zipCAR or surface antigens: Mesothelin, AXL, and/or HER-
2. Two days after transfection, antibiotic (Puromycin (Thermo Scientific #A1113803), 
Zeocin (Thermo Scientific # R25005), or Hygromycin B (Thermo Fisher #10687010)) was 
added to the medium to select for cells that express the transgenes.  
 
3.5.8 Cytokine Release Assays 
Cytokine release assays were carried out using IFN-γ or IL-2 ELISA Kit (BD 
Biosciences #555142, #555190). Primary T cells expressing zipCAR were incubated with 
K562 target cells (10 x 104 cells/well) at an E:T ratio of 2:1 with corresponding zipFvs 
(amount of zipFvs were titrated to give a maximum response). After 24 hr, the supernatant 
was harvested and followed the supplier’s protocol to determine IFN-γ or IL-2 level. In 
order to determine in vivo cytokine release level, murine blood was drawn submandibular 
  
65 
after 24hr of the initial injection of engineered CD8+ T cells and zipFv. Blood plasma was 
harvested by centrifuging collected blood for 10 minutes at 3000 x g. In vivo IFN-γ release 
was measured by Luminex Magpix at BUMC (Boston University Medical Campus) core 
facility. 
 
3.5.9 Luciferase Cytotoxic T Lymphocyte Assay 
Cytotoxicity assays were carried out using bioluminescence previously described 
[165]. Briefly, CAR-T cells were incubated with zipFv and target cells (K562 cells) that 
were engineered to express luciferase at varying effector to target ratio (e.g., E:T=8:1, 4:1, 
2:1, or 1:1) for 4hr at 37 ºC. Initially, target cells were seeded at 75,000 or 100,000 cells 
per well (96-well plate) and zipFv at varying concentrations were added (amount of zipFvs 
were titrated to give a maximum response). Then, engineered T cells were added (unless 
otherwise noted, T cells used in the experiment were not sorted based on the SUPRA CAR 
expression level). After ~4hr incubation, the culture medium was removed to leave 50ul 
per well, then 50ul of prepared luciferase reagent (Promega #E2610) was added to each 
well of the 96-well plate (Corning #3904).  Measurements were performed with the 
SpectraMax M5 (Molecular Devices). Target cell cytotoxicity was calculated using the 
following formula: Cytotoxicity = 100 x [(Total Target cell luminescence – luminescence 
of remaining cells after lysis) / (Total Target cell luminescence)]. 
For in vitro cytotoxicity assay shown in Figures 3.6.2CB, single or dual expressing 
target cells was first added into each well. In both of the cases, both cells were equally 
treated by adding-Axl zipFv. After ~20 minutes of incubation to allow -Axl zipFv to 
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bind to target cells, cells were spun down and washed to remove unbound -Axl zipFv. 
Subsequently, -Her2 zipFv and SUPRA CAR T cells were added to the washed target 
cells sequentially. After ~4hr incubation, luminescence from each well was measured as 
described above. 
3.5.10 Xenograft Mouse Models 
Female NSG mice, 4-6 weeks of age, were purchased from Jackson Laboratories 
(#005557) and maintained in the BUMC Animal Science Center (ASC). All protocols were 
approved by the Institutional Animal Care and Use Committee at BUMC. In order to carry 
out the intraperitoneal xenograft models, NSG mice were initially injected with 7.5 X 106 
luciferized SK-BR-3 intraperitoneally. After 2 weeks or after tumor burden reached ~1010 
luminescence (photons/sec), 35 x 106-CD8+ CAR-T cells were infused intraperitoneally 
along with zipFv. ZipFvs were added every two days for 2 weeks (total of 8 times) at 
specified doses.  For blood tumor model, NSG mice were initially injected with 5 X 106 
luciferized Jurkat tumor cells intravenously. After 3 or 5 days, 2.5 to 10 x 106-CD8+ CAR-
T cells were infused intravenously along with zipFv. ZipFvs were added every day for 6 
or 9 days at specified doses. Tumor burden was measured by IVIS Spectrum (Xenogen) 
and was quantified as total flux (photons per sec) in the region of interest. Images were 
acquired within 30 minutes following intraperitoneal injection of 150mg/kg of D-luciferin 
(PerkinElmer #122799).   
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3.5.11 QUANTIFICATION AND STATISTICAL ANALYSIS 
Statistical significance was determined by student’s T test (two tailed) unless 
otherwise noted. All curve fitting was performed with Prism 7 (Graphpad) and p values are 
reported (not significant = p > 0.05, * = p ≤ 0.05, ** = p ≤ 0.01, *** ≤ 0.001). All error 
bars are represented either SEM or SD. 
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3.6 Figures 
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Figure  3.6.1. Design and characterization of the SUPRA CAR system.   
 (A) Comparison between the conventional CAR and SUPRA CAR design. A SUPRA 
CAR system is composed of a zipCAR and zipFv. A zipCAR has a leucine zipper as the 
extracellular portion of the CAR and zipFv has scFv fused to a cognate leucine zipper that 
can bind to a leucine zipper on zipCAR.  
(B) A SUPRA CAR system targeting multiple tumor antigens using different zipFvs. K562 
cells expressing Her2, Mesothelin, or Axl were co-cultured in vitro with RR zipCAR 
expressing CD8+ human primary T cells (n=3, data are represented as mean ± SD). 
(C) Variables explored for characterization of the SUPRA CAR system: (1) the affinity 
between leucine zipper pairs, (2) the affinity between tumor antigen and scFv, (3) the 
concentration of zipFv, and (4) the expression level of zipCAR. 
(D) Effect of concentration of three zipFvs with leucine zippers (SYN 3, SYN5, and EE) 
that have different affinity to RR zipCAR on IFN- production by primary CD4+ T cells 
(n=3, data are represented as mean ± SD). 
(E) Effect of the zipper affinity, scFv-tumor affinity, and zipCAR expression level on IFN-
 production by primary CD4+ T cells expressing RR zipCAR (n=3, data are represented 
as mean). 
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Figure  3.6.2. Utilizing SUPRA CAR for OFF switch function and combinatorial 
antigens targeting. 
 (A) (Left) Schematic diagram of the SUPRA CAR with an OFF switch zipFv. Three 
competitive leucine zippers that can bind to the EE leucine zipper with different affinities 
are used to tune the T cell activation level. (Right) Cytotoxicity plot demonstrating the 
effect of the competitive zipFvs (n=3, data are represented as mean ± SD). 
(B) Cytotoxicity plot of “OR” gate implementation of the SUPRA CAR system. 
Her2+/Axl+ K562 tumor cells were co-cultured with RR zipCAR expressing CD8+ T cells 
with different zipFv combinations (n=3, data are represented as mean ± SD). 
(C) Using SUPRA CAR system as cell selector. Cells either expressed Her2 or Her2 and 
Axl.  Axl acted as a “safe marker” that can inhibit SUPRA CAR T cell activity (data are 
represented as mean ± SD, statistical significance was determined by Student’s t-test, *** 
= p ≤0.001). 
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Figure  3.6.3. In vivo activity of SUPRA CAR in SK-BR-3 and Jurkat xenograft 
models. 
 (A) (Left) The tumor burden was quantified as the total flux (photons/sec) from the 
luciferase activity of each mouse using IVIS imaging. Compared to RR zipCAR or tumor 
only control groups, the RR zipCAR + EE zipFv group showed significantly reduced tumor 
burden, comparable to conventional Her2 CAR (red arrow indicates injection of engineered 
CD8+ T cells and highlighted region indicates injection of zipFv (every 2 days at 5mg/kg 
for 2 weeks)).  (Right) Representative IVIS images of groups treated with (1) no T cells, 
(2) conventional Her2 CAR, (3) RR zipCAR, and (4) RR zipCAR with EE zipFv at day 41 
(n=4, data are represented as mean ± SEM). 
(B) Representative IVIS images of groups treated with (1) no T cells, (2) RR zipCAR, (3) 
α-Her2 RR zipFv with RR zipCAR (non-binding), and (4) α-Her2 EE zipFv with RR 
zipCAR (complete SUPRA) (day 57, Figure S4B). 
(C) Tumor burden as total flux (photons per sec) of each mouse shown in Figure 3B (n=4, 
data are represented as mean ± SEM). 
(D) In vivo IFN-γ cytokine level after 24 hours of initial CD8+ T cells and zipFv injection 
(n=4, data are represented as mean ± SD). 
(E) (Left) Jurkat tumor cells were injected intravenously at day 0 to immune-compromised 
NSG mice. At day 3, primary human CD8+ T cells expressing RR zipCAR were injected 
once (red arrow) with -Her2-EE zipFv which was dosed every day for 6 days at 3mg/kg 
(highlighted). The tumor burden was quantified as the total flux (photons/sec) from the 
luciferase activity of each mouse using IVIS imaging. (Right) Representative IVIS images 
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of groups treated with (1) no T cells, (2) conventional Her2 CAR, (3) RR zipCAR, and (4) 
RR zipCAR with EE zipFv at day 21 (n=4, data are represented as mean ± SEM, statistical 
significance was determined by Student’s t-test, *= p ≤0.05, ***= p ≤0.001). 
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Figure  3.6.4.  In vivo control of cytokine production by the SUPRA CAR. 
 (A) In vivo IFN-γ cytokine level at 24 hr. In vivo cytokine level increased in a dose-
dependent manner (n=4, data are represented as mean ± SD). 
(B) In vivo IFN-γ cytokine level at 24hr, demonstrating leucine zipper affinity-dependent 
increase of in vivo IFN-γ cytokine (n=4 mice, data are represented as mean ± SD). 
(C) In vivo IFN-γ cytokine level demonstrating the effect of competitive zipFv (n=4 mice, 
data are represented as mean ± SD, the statistical significance was determined by Student’s 
t-test, * = p ≤0.05, *** = p ≤0.001). 
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Figure  3.6.5.  Controlling different signaling domains with orthogonal SUPRA CARs.   
 (A) Design of orthogonal SUPRA CARs that control either CD3 or CD28/4-1BB 
signaling domains. The RR zipCAR and FOS zipCAR contain CD28/4-1BB co-
stimulatory and CD3 signaling domain, respectively.  α-Her2 zipFv binds to the FOS 
zipCAR and activates the CD3domain, whereas the α-Axl zipFv binds to the RR zipCAR 
and activates CD28/4-1BB co-stimulatory domains. CD69 expression, IFN-γ, IL-2, and 
IL-4 secretion were measured as outputs. 
(B) Amount of each zipFv was varied to define signaling strength from each receptor. 
CD69 expression (left) and IFN-γ secretion (right) were measured (n=3, data are 
represented as mean). 
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Figure  3.6.6.  Controlling different cell types with orthogonal SUPRA CARs.   
(A) Design of orthogonal SUPRA CARs that control either CD4+ or CD8+ human primary 
T cells.  The RR zipCAR and FOS zipCAR control CD4+ and CD8+ T cells activity, 
respectively. α-Axl zipFv binds to RR zipCAR and activates CD4+ T cells. α-Her2 zipFv 
binds to the FOS zipCAR and activates CD8+ T cells.  
(B, C) The CD69 expression and IFN-γ measurements showing independent control of 
CD4+ and CD8+ T cells with orthogonal SUPRA CARs (n=3, data are represented as mean 
± SD).  
(D) Forward- and side-scatter FACS plots of the cell mixture after 24 hours co-culture of 
T cells (both CD4+ and CD8+, blue) with Her2+/Axl+ K562 tumor cells (orange). Tumor 
cells are killed efficiently when CD8+ cytotoxic T cells were activated by the α-HER2 
zipFv (representative of three biological replicates). 
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Figure  3.6.7.  Engineering a prosthetic immune system with SUPRA CARs.   
 (A) The SUPRA CAR system enables the flexible and advanced control of signaling in T 
cells, reminiscent of an audio mixing console for controlling audio signals. The affinity 
and dosage of each zipFv are like knobs and dials on the mixing console, which can be 
varied to achieve user-defined T cell activation levels.  Different orthogonal pairs of 
SUPRA CARs are like different channels, which can be utilized to control different 
signaling pathways in the same cells.  (B) The SUPRA CAR system can also be 
implemented in other cell types, thus setting the foundation for creating a prosthetic 
immune system. 
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Figure  3.6.8.  Schematic of SUPRA CAR and effect of different parameters on 
cytotoxicity, Related to Figure 3.6.1.   
 (A) Schematic of zipCAR and zipFv construct designs. ZipCAR composes of leucine 
zipper on the extracellular domain and intracellular signaling domains which contain two 
co-stimulatory signaling domains (CD28 and 4-1BB), and CD3. zipCAR is fused to 
mCherry for visualization. 
(B) (Left) FACS histogram that shows different CAR expression level of CD4+ T cells 
used in Figure 1E  
(Right) Quantified fluorescence value. WT is represented as gray, high CAR expressing 
cells as red and low CAR expressing cells as blue (n=1).  
(C) Effect of concentration of three zipFvs with leucine zippers (SYN3, SYN5, and EE) 
that have different affinity to RR zipCAR on cytotoxicity (n=3, data are represented as 
mean ± SD). 
(D) Effect of zipper affinity and scFv affinity on cytotoxicity (n=3, data are represented as 
mean). 
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Figure  3.6.9.  Comparison of SUPRA CAR with conventional -Her2 CAR and 
characterization of zipFvs, Related to Figures 3.6.1., 3.6.2. and 3.6.5.   
 (A) (Left) Schematic of SUPRA CAR (EE-RR pair) and a-Her2 CAR. (Right) Forward- 
and side-scatter FACS plots of the cell mixture after 24 hours co-culture of T cells (blue) 
with Her2+ K562 tumor cells (orange) (representative of three biological replicates). 
(B, C) The CD69 expression and IFN-γ measurement after 24hr of co-culturing with RR 
zipCAR / - Her2 CAR and Her2+ K562 target cells (n=3, data are represented as mean ± 
SD). 
(D, E) Denaturing SDS-PAGE and western blot images of the different zipFvs used in the 
paper 
(F) Table of expected protein mass (Da) of different zipFvs 
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Figure  3.6.10.  Competitive zipFv screen to tune SUPRA CAR activity and using 
SUPRA as a Cell Selector, Related to Figure 3.6.2. 
 (A) Leucine zippers with different affinities to EE leucine zipper.  
(B) EE zipCAR expressing Jurkat T cells were co-cultured with Her2 expressing K562. 
Then, different zipFvs (α-Her2-SYN2, α-Her2-SYN4, α-Her2-SYN47, or α-Her2-SYN13) 
were added. GFP expression was measured after 24 hours to quantify NFAT promoter 
activity. 
(C) Normalized NFAT promoter activity measured by GFP expression of different zipFvs 
(n=2, data are represented as mean ± SD). 
(D) RR zipCAR expressing CD8+ T cells were co-cultured with Her2 expressing K562. α-
Her2-EE zipFv (22.5nM) was added to activate T cells. Then, a different amount of 
competitive zipFv (90nM, 45nM, and 22.5nM) was added at a different time after EE zipFv 
was added (n=3, data are represented as mean). 
(E) Cell selector with zipFv (α-Axl-SYN13) that does not bind strongly to α-Her2-EE 
zipFv. 
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Figure  3.6.11. Binding between zipFv and zipCAR is required to clear the tumor in 
vivo. Effect of zipFv dose and scFv affinity on tumor burden and in vivo cytokine 
production, Related to Figures 3.6.3. and 3.6.4. 
 (A) Diagram showing the xenograft study described in Figure 3B. Two different zipFvs 
were used; α-Her2-EE zipFv that binds to RR zipCAR strongly and α-Her2-RR zipFv that 
does not bind to RR zipCAR strongly. 
(B) SK-BR-3 breast cancer cells were injected intraperitoneally at day 0 and at day 26 
(black arrow) to immune compromised NSG mice. After verifying tumor establishment, 
RR zipCAR expressing CD8+ T cells (red arrow) were injected along with α-Her2 EE 
zipFv or α-Her2 RR zipFv (dosed every 2 days for 2 weeks at 8mg/kg, highlighted). Tumor 
burden was quantified as total flux (photons/sec) of luciferase activity from each mouse 
using IVIS imaging (n= 4 mice, data are represented as mean ± SEM, statistical 
significance was determined by two-tailed Student t-test, * = p ≤0.05). 
(C) SK-BR-3 breast cancer cells were injected intraperitoneally at day 0 and at day 26 
(black arrow) to NSG mice. Primary human CD8+ T cells expressing the RR zipCAR were 
injected (red arrow) with the α-Her2-EE zipFv (injected every 2 days for 2 weeks at varying 
concentrations, highlighted). Tumor burden was quantified as total flux (photons/sec) from 
luciferase activity of each mouse using IVIS imaging (n=4, data are represented as mean ± 
SEM). 
(D) Tumor burden as total flux (photons per sec) of each mouse shown in Figure S4C at 
day 57 (n=4, data are represented as mean ± SEM) 
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(E) In vivo IFN- release as scFv affinity changes from low (G98) to medium-high affinity 
(ML39, H3B1) (n= 4 mice, data are represented as mean ± SD, statistical significance was 
determined by two-tailed Student t-test, *** = p ≤0.001).  
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Figure  3.6.12.  Tumor clearance of SUPRA CAR in vivo using Jurkat xenograft 
model, Related to Figure 3.6.3. 
(A) Kaplan-Meier survival curves of various groups shown in Figure 3E 
(B) Effect of different T cell dose on tumor burden. (Left) The tumor burden was quantified 
as the total flux (photons/sec) from the luciferase activity of each mouse using IVIS 
imaging (red arrow indicates injection of T cells (day 5) and zipFv was dosed daily for 9 
days at 4mg/kg). (Right) Representative IVIS images of different groups at day 20 (n=4, 
data are represented as mean ± SEM). 
(C) Effect of zipFv dose on tumor burden. (Left) The tumor burden was quantified as the 
total flux (photons/sec) from the luciferase activity of each mouse using IVIS imaging (red 
arrow indicates injection of T cells (day 5) and zipFv was dosed daily for 9 days). (Right) 
Representative IVIS images of different groups at day 20 (n=4, data are represented as 
mean ± SEM). 
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Figure  3.6.13.  Comparison of Humanized SUPRA CAR with EE-RR SUPRA pair 
(A) Schematic of Humanized SUPRA CAR (FOS-JUN pair) and RR-EE SUPRA CAR. 
FACS plots of the cell mixture after 24 hours co-culture of SUPRA CAR T cells with 
Her2+ Jurkat tumor cells. Jurkat tumor cells express blue fluoresce protein (BFP) 
(representative of three biological replicates). 
(B, C) The CD69 expression and IFN-γ measurements after 24hr of co-culturing with FOS 
/ RR zipCAR and Her2+ Jurkat target cells (n=3, data are represented as mean ± SD). 
(D) (Left) The tumor burden was quantified as the total flux (photons/sec) from the 
luciferase activity of each mouse using IVIS imaging (red arrow indicates injection of T 
cells (day 5) and zipFv was dosed daily for 9 days at 4mg/kg). (Right) Representative IVIS 
images of groups treated with (1) no T cells, (2) RR zipCAR (10x106 T cells per mouse), 
(3) FOS zipCAR (10x106 T cells per mouse), (4) RR zipCAR with α-Her2 EE zipFv 
(4mg/kg), and (5) FOS zipCAR with α-Her2 JUN zipFv (4mg/kg) at day 20 (n=4, data are 
represented as mean ± SEM). 
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Figure  3.6.14.  Orthogonal SUPRA CAR screen and controlling different signaling 
domains using orthogonal SUPRA CARs, Related to Figures 3.6.5. and 3.6.6. 
(A) Jurkat T cells expressing different zipCARs were co-cultured with Her2 expressing 
K562 target cells and different zipFvs. GFP expression was used to measure the interaction 
between two leucine zippers. 
(B) In order to identify several pairs of orthogonal SUPRA CARs, we chose 18 zipCARs 
and 30 zipFvs and quantified NFAT promoter activity (n= 2, data are represented as mean). 
(C) Sets of orthogonal SUPRA CARs (n= 2, data are represented as mean). 
(D, E) Quantified IL-2 and IL-4 production when dual orthogonal CARs were activated 
with varying concentration of two zipFvs (n=2 for IL-2 and n=3 for IL-4, data are 
represented as mean, Related to Figure 5A). 
(F) Comparison of quantified CD69 expression, IFN-, IL-2, and IL-4 production when 
the varying concentration of two zipFvs was added as shown in Figures 5B, S7D, and S7E. 
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CHAPTER FOUR: ENGINEERING IMMUNE CELL CONSORTIA WITH 
ADVANCED LOGIC COMPUTATION USING UNIVERSAL CHIMERIC 
ANTIGEN RECEPTORS  
 
 
4.1 Introduction 
 
The human immune system composes of a variety of cell types that constantly sense 
and integrate multiple environmental inputs to defend against disease. Recent findings on 
immune cell-cell interactions led to achieve many novel drug discoveries. For instance, 
Sipuleucel-T (also known as Provenge) has been developed to treat metastatic prostate 
cancer [48]. This treatment utilizes antigen presenting cells (APCs) to stimulate CD4+ 
helper T cells and CD8+ cytotoxic T cells. Furthermore, different checkpoint blocker 
therapies (e.g., CTLA-4 blockade, PD-1 inhibitors, PD-L1 inhibitors) that block 
interactions between immune cells and cancer cells, have shown to be very effective cancer 
immunotherapy [50,166–168].  Despite these successes, responses of checkpoint inhibitor 
treatment are restricted only to subsets of cancer patients [169–171]. Thus, we still need 
better tools to program cell-cell interactions with advanced logic and control capabilities 
to enhance the efficacy of cancer immunotherapy. 
Recently, chimeric antigen receptors (CARs) are utilized as a prominent genetic 
tool for cancer immunotherapy by redirecting the native T cell responses against B cell 
malignancies [110,122,172,173].  CARs are composed of the single-chain variable 
fragment (scFv) fused to T cell signaling domains. When scFv binds to a tumor antigen, 
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CAR T cells activate and eliminate B cell cancers. After demonstrating its efficacy as an 
effective cancer immunotherapy agent, CAR T therapy is now being applied to treat many 
other diseases such as autoimmune diseases by utilizing different types of immune cells 
[52,174]. Although very promising, most of the current CAR T cell therapy has been 
implemented in single subsets of immune cell type. As our immune system is composed of 
many different immune cell types that constantly interact with each other with varying in 
vivo phenotypes, genetic tools that endow inducible control of different immune cell types 
can have a profound impact in designing more effective therapy.  
Current CAR design utilizes fixed sFv design that lacks specificity and flexibility 
in controlling T cell responses, thereby leading to CAR T toxicities [58,59,107]. To 
enhance the target specificity of CARs, combinatorial antigen sensing CAR designs that 
allow increased target specificity were introduced [62,63].  However, the main limitation 
of these combinatorial receptors is that these approaches still utilize fixed scFvs that require 
re-engineering of T cells to switch target specificities. Also, these receptors have been 
shown to incorporate two distinct tumor targets, but more stringent target specificity may 
be needed [175]. 
There have been several studies demonstrating the importance of host immune 
environment on tumor immunity [72,176]. For instance, compositions of innate dendritic 
cells and natural killer cells in tumor microenvironment have been demonstrated to 
improve the efficacy of cancer immunotherapy [177,178]. Furthermore, several immune 
cell populations have been demonstrated to increase cancer progressions and reduce 
immunotherapy responses. For instance, it is now well characterized that tumor-associated 
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macrophages (TAMs) have suppressive function and blocking TAM suppression improves 
the response of adoptive T cell therapy [179,180]. Also, the increase in a number of tumor-
infiltrating neutrophils and monocyte has been associated with poor patient survival [181]. 
These results imply the importance of manipulating the host immune system to enhance 
the efficacy of immunotherapy. 
Recently, we developed split, universal, and programmable (SUPRA) CAR that 
enables fine control of immune cell responses [64]. SUPRA CAR is composed of zipFv 
and zipCAR, where zipFv is composed of scFv fused to leucine zipper and zipCAR is 
composed of extracellular leucine zipper domain fused to intracellular T cell signaling 
domains. Thus, zipFv mediates binding between zipCAR and tumor antigens. With 
SUPRA CAR, we previously demonstrated regulating ON/OFF switch, fine-tuning of T 
cell activation, and controlling two orthogonal inputs in human primary T cells. 
To generate synthetic cell-cell interactions with advance logical capabilities, we 
engineer seven innate and adaptive immune cells with SUPRA CAR and illustrate that we 
can successfully redirect the activity of different immune cells. Next, we build logic gates 
in different immune cell types and further expand the multi-input logic gate by integrating 
three inputs in a single cell using orthogonal SUPRA CARs. These logic gates perform as 
basic tools for constructing synthetic immune cell consortia and also improve the 
specificity of CAR T cell therapy. We also show regulatory T cell-mediated immune 
suppression and intercellular logic gate by engineering immune cell-cell interaction. 
Lastly, we also demonstrate endogenous immune cell polarization using SUPRA CARs. 
Thus, these wide-range SUPRA CAR applications imply its versatility as a platform for 
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engineering cell-cell interactions with advanced logical functions.  
 
4.2 Results 
4.2.1 SUPRA CARs Can Activate Diverse Adaptive and Innate Immune Cell Types 
 
To expand cell types that SUPRA CARs can redirect, we first tested various T cell 
subtypes, NK cell, and macrophage. These cell types were transduced to express SUPRA 
CARs and co-cultured with or without -Her2 zipFvs in the presence of the Her2-
expressing NALM6 target cells.  Consistent with our previous report [64], SUPRA CAR 
can efficiently induce target cell killing by CD8+ T cells (Figure 4.6.1A).  As subtypes of 
CD4+ T cells are highly diverse, and cytokines released by each subtype regulate the 
direction of the immune responses [182], we wanted to illustrate a possibility of SUPRA 
CAR controlling different subsets of CD4+ T cells. Here, we differentiated naive CD4+ T 
cells to Th1 and Th2 cells. Then, we demonstrated that SUPRA CAR-containing in vitro 
differentiated Th1 and Th2 cells were activated by the corresponding zipFvs and secreted 
IFN- and IL-4 respectively (Figures 4.6.1B, 1C, and 4.6.7A).  Additionally, regulatory 
T (Treg) cells are a unique subtype of CD4+ T cells that show various antigen-dependent 
immunosuppressive phenotypes such as secretion of IL-10 and expression of CTLA-4 
[183] and have been demonstrated to be effective to treat the autoimmune disorder [184]. 
A pan-T cell activation marker, CD69, was upregulated in SUPRA CAR-containing Treg 
cells when corresponding zipFv was added (Figures 4.6.1D and 4.6.7B).  In order to 
increase Treg stability, the Foxp3 transcription factor was overexpressed with RR zipCAR 
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(Figure 4.6.7C). Another T cell subtype, gamma delta T cells (γδ T cells) express a unique 
T-cell receptor (TCR) composed of a γ-chain and a δ-chain. γδ T cells are low abundance 
in the body but are anticipated to be a remarkable cell type for solid tumor therapy because 
of their specific tissue homing ability [185]. Here, we demonstrated that SUPRA CAR γδ 
T cells were activated and secreted IFN- after the corresponding zipFv was added 
(Figures 4.6.1E, 4.6.7D, and 4.6.7E).  Natural killer (NK) cell is a type of lymphoid cells 
and is known to mediate anti-cancer effects without the risk of inducing graft-versus-host 
disease (GvHD) [186]. In addition to donor-derived primary NK cells, NK-92, the 
established NK cell line, is also being developed for adoptive immunotherapy as the safety 
of infusion of irradiated NK-92 cells has been demonstrated in phase I clinical trials [187–
189]. We utilized IL-2-producing NK-92 line, NK-92MI, and demonstrated that SUPRA 
CAR can induce antigen-specific cytolysis of the NK cell (Figure 4.6.1F). Finally, the 
macrophage is a type of innate immune cells and performs phagocytosis of opsonized 
pathogens and apoptotic cells. Through antigen presentation and release cytokines, 
macrophage controls activation and differentiation of CD4+ helper T cells and immune 
responses. It has been reported that CD3 domain-containing conventional CAR induced 
macrophages to phagocyte antigen-expressing cells [190]. SUPRA CAR also re-directed 
macrophage phagocytosis in a zipFv-dependent manner (Figure 4.6.1G).  Together, we 
can control diverse phenotypes of immune cells with the single integrated SUPRA CAR 
system. 
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4.2.2 SUPRA CARs Can Logically Respond to Combinatorial Antigen  
 
Lack of target specificity is one of the main challenges in CAR-T cell therapy. As 
many of the antigens overexpressed on cancer cells are also expressed on normal cells 
[60,191,192], to enhance tumor specificity, combinatorial CAR systems have been 
previously reported [62,82]. However, this function largely depends on the affinity 
between scFv and a tumor antigen, and thus fixed scFv CAR designs are not ideal for 
controlling the combinatorial CARs. To overcome this deficiency, we previously 
developed tunable combinatorial AND logic using orthogonal SUPRA CARs [64].  
However, it was simply a proof-of-concept illustration as combinatorial logic was only 
demonstrated in conventional CD4+ T cells. Here, to expand SUPRA AND-gate in more 
clinically relevant T cell types, we first engineered primary CD8+ T cell to express two 
orthogonal SUPRA CARs to regulate different signaling pathways (Figures 4.6.2A and 
4.6.8.A). FOS zipCAR (binds to -Her2-SYN9 zipFv) has an only CD3 domain, whereas 
RR zipCAR (binds to -Axl-EE zipFv) has CD28 or 4-1BB co-stimulatory domains, which 
are being used in clinical CAR T cell therapy [193,194].  Both types of engineered T cells 
showed synergistic upregulation of target cell killing with the addition of two zipFvs, 
demonstrating their clinical utility (Figures 4.6.2B and 4.6.2C). Compared to CD28, 4-
1BB expressing CAR showed higher basal activity when the 4-1BB signaling domain was 
activated and CD28 expressing cells performed AND logic in the wide range of zipFv 
concentration than those of 4-1BB.  
Regulatory T (Treg) cells are a unique subset of CD4+ T cells that are becoming 
promising therapeutic agents to treat many different diseases including autoimmune 
  
105 
disorders [184,195,196]. Even though multiple clinical trials are ongoing using polyclonal 
Treg cells, the use of polyclonal Treg cells with a variety of specificity can bring systemic 
immunosuppression [197]. For instance, there has been a clinical trial where the adoptive 
transfer of umbilical cord-derived polyclonal Treg cells increased viral reactivation [198].  
In order to enhance the specificity of Treg cells, we engineered Treg cells to express SYN6 
zipCAR (binds to -Axl-SYN5) containing CD3 domain and SYN1 zipCAR (binds to -
Her2-SYN2) containing CD28 co-stimulatory domain. We measured CTLA-4 expression 
which is an activation marker and plays an important role in immunosuppression [199] and 
demonstrated that this CD3 /CD28 AND logic was functional in Treg cells (Figures 
4.6.2D and 4.6.8B). Together, the combination of CD3 and CD28 signaling domains acts 
as a fine-tunable intracellular AND-gate in clinically relevant cell types. 
 
4.2.3 BTLA-derived Co-inhibitory Signaling Domain Performs NOT Logic 
 
We also developed NOT gate in CAR T cells (Figure 4.6.3A). Previous studies 
have demonstrated the use of inhibitory domains such as PD-1 and CTLA-4 in CAR design 
[82], but there are other various co-inhibitory domains that can be utilized to inhibit T cell 
responses [144]). Here, we utilized different co-inhibitory signaling domains (PD-1, 
LAG3, TIM3, BTLA, CTLA-4) and validated their functions in SUPRA CAR design 
(Figure 4.6.9A). Initially, CD4+ T cells and CD8+ T cells were transduced with dual 
SUPRA CARs: 1) FOS zipCAR with CD28 and CD3 signaling domains and 2) RR 
zipCAR with different inhibitory domains. For dual SUPRA CAR expressing CD4+ T 
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cells, activation of B and T lymphocyte associated (BTLA) strongly inhibited IFN- 
production in CD4+ T cells (Figure 4.6.3B). However, the effect of BTLA stimulation was 
not as high in CD8+ T cells compared to that of CD4+ T cells measured by IFN- level 
(Figure 4.6.9C). Also, BLTA activation did not inhibit killing efficiency, as previously 
reported [200] (Figure 4.6.9D). Next, we changed the immune cell type from T cells to 
NK cells in order to develop NOT logic that can inhibit target killing efficiency. We 
initially screened several activation domains  (CD3, CD28- CD3, NKG2D, 2B4, DAP12, 
CD28, and ICOS) that can upregulate NK cell response and selected 4 domains (CD3, 
CD28- CD3, 2B4, and DAP12) that induced high killing efficiencies (Figures 4.6.3C and 
4.6.10A). Then, we tested whether activation of BTLA in NK cell can suppress target cell 
cytolysis when also stimulated by activation domain (Figure 4.6.10B). Surprisingly, the 
simulation of  BTLA significantly reduced the killing efficiency of CARs containing CD3 
alone or 2B4 (Figure 4.6.3D). Next, we varied the -Her2-SYN9 and -Axl-EE zipFvs to 
detect ranges of zipFv concentration that endow NOT logic function in NK cells (Figure 
4.6.3E).  These results indicate that not only the choice co-inhibitory domain but also the 
selection of the activating domain and the immune cell type are important for developing 
NOT logic gates. 
  
4.2.4 SUPRA CARs Can Organize Multi-logic Gate in Single Cell 
 
In order to enhance logical programmability of engineered immune cells, we tested 
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if we can combine AND logic and NOT logic in the single cell.  Based on previous 
screening in Jurkat T cells, we decided to use three orthogonal SUPRA CARs to handle 3 
orthogonal inputs [64]. As expected, three orthogonal SUPRA CARS in primary human T 
cells showed minimum cross-reactivity (Figure 4.6.11A).  We expressed three zipCARs 
in T cells by using two vectors where one vector contains P2A ribosomal skipping 
sequence to express both zipCARs and the other vector contains puromycin resistant gene 
to express third zipCAR (Figure 4.6.11B). We transduced T cells with these two virus 
vectors and selected with puromycin at 2ug/ml concentration. As expected, activation of 
CD28 and CD3 significantly increased IFN- production compared to activation of CD28 
or CD3 alone. (Figure 4.6.4A). Also, activation of BTLA significantly reduced IFN- 
production  In order to demonstrate its generalizability in different cell types and to 
identify the range of zipFv concentration that confers logic capability, we also transduced 
CD4+ T cells with three zipCARs (Figure 4.6.4B). As expected, it shows synergistic IFN-
 upregulation (X-Y plane). Furthermore, BTLA inhibited IFN- production in zipFv does 
dependent manner (Z axis). These data demonstrate the first three input multi-logic gates 
in a single T cell that can be used to enhance target specificity.  
  
4.2.5 Engineering Cell-Cell Communication with SUPRA CARs to Achieve 
Intercellular NOT Logic  
 
Here, we engineered intercellular communication using different types of T cells to 
demonstrate diverse logic capability. Regulatory T (Treg) cells suppress inflammatory 
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immune responses in the antigen-dependent manner [183]. Based on this phenotype, 
several types of CAR-expressing Treg cells are being developed to treat various 
inflammatory disorders [161,162,201]. Thus, we utilized SUPRA CAR-equipped Treg 
cells to demonstrate engineering of a simple synthetic cell-cell communication in an 
inducible manner. We co-cultured FOS zipCAR expressing conventional CD4+ T (Tconv) 
cells with RR zipCAR-expressing Treg cells in the presence of target cells that express 
Her2 and Axl (Figure 4.6.5A). When we added -Her2-SYN9 zipFv which activates FOS 
zipCAR expressed on Tconv cells, 40% of Tconv cells proliferated (Figures 4.6.5B and 
4.6.5C). However, activating RR zipCAR expressing Treg cell activation by -Axl-EE 
zipFv inhibited proliferation of Tconv cells to the same proliferation level as no zipFv 
conditions (Figures 4.6.5B and 4.6.5C). This demonstrates that we can now use 
orthogonal SUPRA CARs in different immune cell types to achieve intercellular NOT 
logic.  
 
4.2.6 Controlling Endogenous Immune System with SUPRA CARs 
 
Many of the CAR treated patients undergo symptom called cytokine release syndrome 
(CRS). Recently, it has been demonstrated that endogenous immune cells, especially 
macrophages, to be a key player in the development of CRS [202,203]. This illustrates that 
tools to engineer interaction between engineered immune cells and the endogenous 
immune system can be important to enhance the safety of current CAR-T cell therapy. 
Since SUPRA CARs can engineer Th1 and Th2 cells (Figures 4.6.1B and 4.6.1C), we 
  
109 
tried to demonstrate if we can control the endogenous immune system indirectly by 
manipulating SUPRA CAR-expressing Th1 and Th2 cells. Th1 cells rely on Th1 cytokines 
(e.g., IFN-and Th2 cells rely on Th2 cytokines (e.g., IL-4) to regulate innate and 
adaptive cellular immunity. As a proof of concept to demonstrate engineering endogenous 
immune system, we utilized a monocyte/macrophage cell line THP-1 because 
macrophages polarize to pro-inflammatory M1 or anti-inflammatory M2 after receiving 
IFN- and   IL-4, respectively (Figure 4.6.12A). We co-cultured four cell types including 
1) antigens-expressing Nalm-6, 2) RR zipCAR expressing Th1 cells, 3) FOS zipCAR 
expressing Th2 cells, and 4) THP-1-derived macrophages in vitro (Figure 4.6.6A). RR 
zipCAR containing Th1 cells secreted IFN- and macrophage polarized to M1 state 
measured by M1 surface markers (e.g., HLA-DR and CCR7) when -Axl-EE zipFv was 
added (Figure 4.6.6B and 4.12B). FOS expressing Th2 cells secreted IL-4 and 
macrophage polarized to M2 state measured by M2 surface marker (e.g., CD206) (Figure 
4.6.6B and 4.6.12B). These data demonstrate that SUPRA CAR platform can be 
implemented in diverse cell types to engineer the endogenous immune system for different 
therapeutic purposes.  
 
4.3 Discussion 
 
4.3.1 SUPRA CAR can redirect the activity of both innate and adaptive immune cells 
 
Many of current cellular immunotherapy is utilizing a single subset of immune cell 
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type, limiting the therapeutic potential of cell-based therapy. Even when the mixture of 
cells is used, we lack independent and inducible control over different cell types. Here, we 
demonstrate that SUPRA CAR can redirect immune responses of both innate and adaptive 
immune cell types, thereby showing that single SUPRA CAR system can harness different 
phenotypes from a variety of immune cell types, including cytolysis and phagocytosis of 
tumor cells, secretion of various cytokines, and suppression of other immune cells. By 
utilizing orthogonal SUPRA CARs, different immune cell types can now be independently 
regulated which can form the basis of constructing synthetic immune cell consortia.   
 
4.3.2  Engineering Intercellular Communication with SUPRA CARs 
 
Engineering intercellular communication with the novel genetic tool is intriguing 
and has potential use in clinical settings. As many clinical trials are ongoing using Treg 
cells to treat GVHD or tissue rejection during transplantation and autoimmune diseases 
[161,197,201],  here we demonstrate inducible and independent control of conventional T 
cells and regulatory T cells using orthogonal SUPRA CARs. This approach can be useful 
in managing symptoms during transplantation and autoimmune diseases. For instance, in 
an autoimmune disease setting, we can use convention T cells to target autoimmune B cells 
[174] or even autoreactive CD4+ T cells and use SUPRA CAR engineered Treg to protect 
the tissue/cell of our interest at the same time to enhance the efficacy of Treg implemented 
treatment.  
We also demonstrate how we can use engineered cells to manipulate the 
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endogenous immune system. Recent studies have demonstrated the importance of 
endogenous immune system on the efficacy of immunotherapies  [72,176,177]. 
Furthermore, many patients who received CAR T therapy undergo cytokine release 
symptom [57,58] and recently it has been demonstrated that macrophages play a crucial 
role in inducing CRS [202,203]. Thus, genetic tools that enable engineering host immune 
cells could accelerate the efficacy and safety of CAR T cell therapy. As a proof of concept, 
we engineered Th1 and Th2 cells to express orthogonal SUPRA CARs and induced these 
cells to direct polarization of macrophages, demonstrating that SUPRA CAR is an 
advanced genetic tool that can manipulate host immune system. 
 
4.3.3 Orthogonal SUPRA CARs Enable Advanced Logical Function in Different 
Immune Cell Types 
 
Here, we demonstrate that SUPRA CAR can perform complicated logic in different 
types of immune cells. First, we show AND logic in clinically relevant cell types: both 
CD8+ T cells and Treg cells to enhance target specificity. Unlike previously reported 
combinatorial CAR [62], SUPRA CAR allows inducible control of each SUPRA CAR to 
regulate signaling strength from each receptor. Furthermore, by implementing the BTLA 
co-inhibitory signaling domain, we implement NOT logic in both CD4+ and CD8+ T cells, 
and NK cells. We screened for different activation domains of NK cells and identified that 
BTLA can downregulate both CD3 and 2B4 activation domains. We also verified that 
activation of BTLA significantly decreases cytokine secretion, demonstrating its potential 
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utility in the clinic to prevent cytokine release syndrome. Also, to further advance logic 
capability, we implemented three-input logic gate in CD4+ and CD8+ T cells and 
demonstrate “a AND b NOT c” logic that can greatly enhance target specificity. Diverse 
SUPRA CAR features demonstrate the utility of this platform as a general approach to 
engineer immune cells with advanced logic capabilities and to engineer immune cell-cell 
interaction that can improve the efficacy of cell-based immunotherapy. 
 
4.4 Conclusion 
 
Chimeric antigen receptors (CARs) expressing T cells have demonstrated to be very 
effective anti-cancer therapy.  However, current CAR T cell therapy only utilizes a single 
subset of immune cell type. In addition, we lack genetic tools to regulate different cell types 
in an inducible manner that could transform the efficacy of CAR T cell therapy. 
Furthermore, we still need to enhance target specificity of CAR T cell to enhance its safety. 
Here, we significantly expanded the previously reported SUPRA CAR platform. We first 
show that SUPRA CAR can redirect immune responses of both innate and adaptive 
immune cell types, thereby illustrating that single SUPRA CAR can be used to control 
different phenotypes of various immune cells. Using different cell types, we also 
engineered intercellular communication between two different immune cells and 
demonstrated regulatory T cell-mediated immune suppression. In addition, inducible 
control of different cell types can be used to manipulate the endogenous immune system 
using SUPRA CAR T cells, a capability that has not been achieved before. Lastly, we 
expanded SUPRA CARs with advanced logic and control features using a co-inhibitory 
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signaling domain which can be used to increase target specificity. Overall, diverse SUPRA 
CAR features illustrate the versatility of this platform as a general approach to engineer 
immune cell phenotypes to improve safety and efficacy of cellular immunotherapy. 
 
4.5 Methods 
4.5.1 zipCAR Receptor Construct Design 
zipCARs were designed by fusing different leucine zippers (Reinke et al., 2010; Thompson 
et al., 2012) to the hinge region of the human CD8α chain and transmembrane and 
cytoplasmic regions of the signaling domains including co-stimulatory domains (CD28, 4-
1BB, ICOS, OX40, CD27, GITR);  co-inhibitory domains (PD-1, LAG3, TIM3, BTLA, 
CTLA-4); and NK activating domains (2B4, DAP12, and NKG2D). They were under 
SFFV promoter for all primary T cells and NK cells experiments. All zipCARs contain 
surface tags and fused to fluorescent proteins or puromycin resistant gene to verify their 
expression. 
 
4.5.2 zipFv Construct Design 
The general design of zipFv is as follows. scFv (α-HER2, α-Axl, α-CD19, α-MESO, and 
α-CD5) is linked by a 35-aa glycine/serine linker to a leucine zipper. Constructs were 
cloned into pSecTag2A vectors (Thermo Fisher) for transient expression. These vectors 
contain the CMV promoter, murine Ig-k-chain leader sequence, C-terminal c-myc epitope, 
and a 6X His tag for purification. 
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4.5.3 Expression and Purification of zipFv 
For transient expression of the protein, Freestyle 293-F cells (Thermo Scientific #R79007) 
were transfected with pSecTag2A plasmid according to the supplier’s protocol. After 4 
days of culture, cells were pelleted by centrifugation at 300 × g for 5 minutes, and 
supernatant protein expression was confirmed by Coomassie gel stain (Thermo Scientific 
#24592) and western blot (abcam #ab62928). Proteins derived from transient transfection 
were purified as follows. The supernatant was passed through columns containing ProBond 
nickel chelating resin (Thermo Scientific #R80101). Then, each column was washed four 
times with native purification buffer (50 mM NaH2PO4 and 0.5 M NaCl pH 8.0) plus 20 
mM imidazole (Sigma Aldrich # I5513) and eluted three times with native purification 
buffer plus 250mM imidazole concentrations. Eluted proteins were concentrated to ~2ml 
and dialyzed into 1× PBS (Thermo Scientific #AM9625). After dialysis, the protein was 
verified by western blot and SDS-PAGE gel electrophoresis and protein concentration was 
quantified by the Pierce BCA Protein Assay Kit (Thermo Scientific # 23227). 
 
4.5.4 Primary Human T cells Isolation and Culture 
Normal whole peripheral blood was obtained from Boston Children’s hospital, as approved 
by the University Institutional Review Board (IRB) approved consent forms and protocols. 
Primary human CD4+ and CD8+ T cells were isolated from anonymous healthy donor 
blood by negative selection (STEMCELL Technologies #15062 and #15063). T cells were 
cultured in human T cell medium consisting of X-Vivo 15 (Lonza), 5% Human AB serum 
(Valley Biomedical #HP1022), 10 mM N-acetyl L-Cysteine (Sigma-Aldrich #A9165), 
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55uM 2-mercaptoethanol (Thermo Scientific #31350010) supplemented with 50 units/mL 
IL-2 (NCI BRB Preclinical Repository). T cells were cryopreserved in 90% heat-
inactivated FBS and 10% DMSO. 
Regulatory T cells (Tregs) were isolated from whole blood using immunomagnetic 
cell isolation kit (STEMCELL Technologies cat# 18063 or cat#17861) and were cultured 
initially in human T cell medium consisting of X-Vivo 15 (Lonza), 5% Human AB serum 
(Valley Biomedical #HP1022), 10 mM N-acetyl L-Cysteine (Sigma-Aldrich #A9165), 55 
uM 2-mercaptoethanol (Thermo Scientific #31350010) supplemented with 200 units/mL 
IL-2 (NCI BRB Preclinical Repository). N-acetyl L-Cysteine and 2-mercaptoethanol were 
removed during the Treg suppression experiment. Gamma delta (γδ) T cells were isolated 
from whole blood using immunomagnetic negative selection cell isolation kit 
(STEMCELL Technologies cat# 19255) and were activated with Zoledronic acid 3 ug/ml 
(Sigma-Aldrich #1724827). After 5 days of activation, γδ T cells were transduced with 
lentivirus as shown below.  
 
4.5.5 Lentiviral Transduction of Human T cells and NK cells 
Replication-incomplete lentivirus was packaged via transfection of HEK293FT cells 
(Invitrogen) with a pHR transgene expression vector and the viral packaging plasmids: 
pMD2.G encoding for VSV-G pseudotyping coat protein (Addgene #12259), pDelta 8.74 
(Addgene#22036), and pAdv (promega). One day after transfection, viral supernatant was 
harvested every day for 3 days and replenished with pre-warmed Ultraculture media 
(Lonza #12-725F) with 2mM L-glutamine, 100 U/ml penicillin, 100 ug/mL streptomycin, 
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1 mM sodium pyruvate, and 5 mM sodium butyrate. Then, the harvested virus was purified 
through ultracentrifugation or concentrated with Lentivirus concentrator (Takara 
#631232). One day before transduction, T cells were stimulated with Human T-activator 
CD3/CD28 Dynabeads (Thermo Scientific #11132D) at a 1:2 cell:bead ratio and cultured 
for 24 hr. After viral supernatant purification or concentration, rectronectin (Clontech 
#T100B) was used to transduce cells. Briefly, non-TC treated 6-well plates were coated 
with rectronectin following the supplier’s protocol. Then, concentrated viral supernatant 
was added to each well and spun for 90 min at 1200xg. After centrifugation, viral 
supernatant was removed and 4 ml of previously activated human T cells or NK-92MI cells 
were added. Cells were spun at 1200g for 60 min and moved to an incubator at 37 ºC. 
4.5.6 Primary human Th1 and Th2 cells differentiation 
Normal whole peripheral blood was obtained from Boston Children’s hospital, as approved 
by the University Institutional Review Board (IRB) approved consent forms and protocols. 
Primary human naïve CD4+ were isolated from anonymous healthy donor blood 
(STEMCELL Technologies #19555). After naïve CD4+ T cell isolation, Th1 and Th2 cells 
were differentiated using the supplier’s protocol (R&D cat. #CDK001 and #CDK002). 
Briefly, naïve CD4+ T cells were activated with Dynabeads (Thermo Scientific #11132D) 
at a 1:2 cell:bead ratio and cultured for 24 hr with Th1/Th2 differentiation media. One day 
after T cell activation, primary human T cells were transduced with the methods mentioned 
above. During culture, T cells were cultured in T cell differentiation media (Th1 or Th2 
depending on the experiment) for at least 14 days. 
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4.5.7 Cancer Cell Lines 
The cancer cell lines used were K562 myelogenous leukemia cells (ATCC # CCL-243), 
Jurkat T cells, NALM-6 (ATCC #CRL-3273), THP-1, and NK92-MI (ATCC # CRL-
2408). K562, Jurkat, NALM-6 and THP-1 cells were cultured in RPMI-1640 (Lonza#12-
702Q) with 5% (v/v) heat-inactivated FBS, 2mM L-glutamine, 100 U/ml penicillin and 
100 ug/mL streptomycin. NK92-MI cells were cultured in human T cell medium consisting 
of X-Vivo 10 (Lonza), 5% Human AB serum (Valley Biomedical #HP1022), 2 mM L-
glutamine, 100 U/ml penicillin and 100 ug/mL streptomycin.  Jurkat, K562, and NALM-6 
cells were electroporated with the PiggyBac Transposon system (System biosciences) to 
stably express surface antigens. Two days after transfection or transduction, antibiotic 
(Puromycin (Thermo Scientific #A1113803), zeocin (Thermo Scientific # R25005), or 
Hygromycin B (Thermo Fisher #10687010)) was added to the medium or FACS sorted to 
select for cells that express the transgenes.  THP-1 cells were transduced using lentivirus 
to stably express zipCAR. 
4.5.8 Cytokine Release Assays  
Primary T cells expressing zipCAR were incubated with target cells (10 x 104 cells/well) 
at an E:T ratio of 2:1 or 1:1 with corresponding zipFvs. After 24 hr, the supernatant was 
harvested and followed the supplier’s protocol to determine cytokine release level. In order 
to determine in vivo cytokine release level, murine blood was drawn submandibular after 
24 hr of the initial injection of engineered immune cells and zipFv. Blood plasma was 
harvested by centrifuging collected blood for 10 minutes at 3000 x g. In vivo IFN-γ release 
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was measured by Luminex Magpix at BUMC (Boston University Medical Campus) core 
facility. 
 
4.5.9 Cytotoxicity Assays  
Cytotoxicity assays were carried out using bioluminescence as previously described (Fu et 
al., 2010) or using Flow cytometry (FACS). Briefly, for bioluminescence assay, CAR-T 
cells were incubated with zipFv and target cells that were engineered to express luciferase 
for 4hr at 37 ºC. Culture medium was removed to leave 50ul per well, then 50ul of prepared 
luciferase reagent (Promega #E2610) was added to each well of the 96-well plate (Corning 
#3904).  Measurements were performed with the SpectraMax M5 (Molecular Devices). 
Target cell cytotoxicity was calculated using the following formula: Cytotoxicity = 100 x 
[(Total Target cell luminescence – luminescence of remaining cells after lysis) / (Total 
Target cell luminescence)]. For cytotoxic assay using flow cytometry, CAR-T cells or 
CAR-NK cells were incubated with zipFv and target cells for 24hr at 37 ºC. Prior to flow 
cytometry, control samples containing only the target cells were used to set a flow 
cytometry gate for intact target cells based on forward and side scatter patterns that had 
been previously confirmed to exclude apoptotic cells. Also, fluorescence markers were 
used to further identify the target cells. This gate was applied to all other samples. Live 
target cell number was calculated and target cell cytotoxicity was calculated using the 
following formula:  Cytotoxicity = 100 x [(Total live target cell number – the number of 
remaining live cells after lysis) / (Total live target cell number)]. 
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4.5.10 Treg suppression assay  
Effector T cells were stained with CellTrace dye (Thermo Fisher Scientific cat# C34557) 
following the manufacturer’s instructions.  NALM-6 target cells expressing HER2 ligand 
were treated with 3ug/mL mitomycin C (Sigma-Aldrich cat#M4287) to make target cells 
replication-incompetent. Treg cells and Teff cells were mixed at 1:1 or 2:1 ratio with target 
cells. zipFvs were also added to final concentrations. Cells were collected for flow 
cytometry analysis after incubation for 4 days. 
 
4.5.11 Phagocytosis Assays   
Two days before phagocytosis assays, zipCAR containing human THP-1 cells were 
activated with Phorbol 12-Myristate 13-Acetate (PMA; Fisher Scientific) with 25 ng/ml 
and seeded into TC-treated 96 well plate (15 x 104 cells/well). One day after activation, 
media in every 96 wells was replaced with new media without PMA and incubated at 37 
ºC. After 24 hr, NALM-6 target cells were stained with CellTrace dye (Thermo Fisher 
Scientific cat# C34557) following manufacturer’s instructions and added into each well 
(15 x 104 cells/well) with the corresponding zipFv.  Cells were spun down by 
centrifugation at 400 × g for 1 minute. X minute after co-culture, cells were treated with 5 
mM EDTA (Fisher Scientific) in PBS for 15 minutes at 4 ºC and stained with CD44 
antibody (Biolegend #338806) to label THP-1 macrophages and cells were collected for 
flow cytometry analysis. Prior to flow cytometry, control samples containing only the 
target cells were used to set a flow cytometry gate for intact target cells based on forward 
and side scatter patterns that had been previously confirmed to exclude apoptotic cells. 
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Also, fluorescence markers were used to further identify the target cells. Number of 
phagocytosed cells were calculated by dual positive cells (APC+ [anti-human CD44] and 
violet+ [CellTrace]). This gate was applied to all other samples. Target cell phagocytosis 
was calculated using the following formula:  % phagocytosis = 100 x [(Number of THP-1 
macrophage that are dual positive after co-culture) / (Total live THP-1 macrophage cell 
number)].    
 
4.5.12 M1 and M2 Polarization Assay  
In TC-treated 96 well plate, THP-1 cells were treated with 25 ng/mL PMA for 6 hr to 
differentiate macrophages and then cultured for 2 days in new media without PMA. 
Antigens-expressing Nalm-6 (1 x105 cells/well), RR-CAR-expressing Th1 cells (1 x104 
cells/well), and FOS-CAR-expressing Th2 cells (2.5 x104 cells/well) were added to THP-
1 with or without corresponding 4 nM zipFvs. THP-1 cells were detached with 5 mM 
EDTA in PBS 24 hr after starting co-culture. THP-1 cells were stained with antibodies 
against M1 and M1 markers and analyzed by flow cytometry (Attune NxT; Thermo Fisher 
Scientific). 
 
4.5.13 Quantification and Statistical Analysis  
Statistical significance was determined by student’s T-test (two-tailed) unless otherwise 
noted. All curve fitting was performed with Prism 7 GraphPad) and p values are reported 
(not significant = p > 0.05, * = p ≤ 0.05, ** = p ≤ 0.01, *** ≤ 0.001). All error bars represent 
either SEM or SD. 
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4.6 Figures 
 
Figure  4.6.1. The Intracellular AND Logic with different signaling domains. 
(A) Cytotoxicity by RR zipCAR expressing CD8+ T cells.  NALM6 cells expressing Her2 
were co-cultured in vitro with RR zipCAR expressing CD8+ human primary T cells with 
and without -Her2-EE zipFv (n=3, data are represented as mean ± SD). 
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(B) IFN- cytokine level from RR zipCAR expressing in vitro differentiated Th1 cells. 
NALM6 cells expressing Her2 were co-cultured with RR zipCAR expressing Th1 cells 
with and without -Her2-EE zipFv (n=3, data are represented as mean ± SD). 
(C) IL-4 cytokine level from RR zipCAR expressing in vitro differentiated Th2 cells. 
NALM6 cells expressing Her2 were co-cultured with RR zipCAR expressing Th2 cells 
with and without -Her2-EE zipFv (n=3, data are represented as mean ± SD). 
(D) CD69 expression level from RR zipCAR-FoxP3 expressing isolated Treg cells 
(CD4+CD25hiCD127low). NALM6 cells expressing Her2 were co-cultured with RR 
zipCAR expressing Treg cells with and without -Her2-EE zipFv (n=3, data are 
represented as mean ± SD). 
(E) IFN- cytokine level from FOS zipCAR expressing isolated γδ T cells. NALM6 cells 
expressing Her2 were co-cultured with FOS zipCAR expressing γδ T cells with and 
without -Her2-SYN9 zipFv (n=3, data are represented as mean ± SD). 
(F) Cytotoxicity by RR zipCAR expressing NK-92MI cells.  NALM6 cells expressing Her2 
were co-cultured in vitro with RR zipCAR expressing NK cells with and without -Her2-
EE zipFv (n=3, data are represented as mean ± SD). 
(G) Phagocytosis by RR zipCAR expressing THP-1 macrophages. NALM6 cells 
expressing Her2 were co-cultured in vitro with RR zipCAR expressing THP-1 
macrophages with and without -Her2-EE zipFv (n=3, data are represented as mean ± SD). 
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Figure  4.6.2. The Intracellular AND Logic with different signaling domains. 
(A) Diagram of intracellular AND logic  
(B) Primary human CD8+ T cells were transduced with FOS zipCAR containing CD3 
domain and RR zipCAR containing CD28 domain.  Cytotoxicity against Her2- and Axl-
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expressing Nalm6 was measured 24 hours after adding anti-Her2-SYN9 and/or anti-Axl-
EE zipFvs.  The heat map indicates cytotoxicity at varying zipFv concentrations (n=3, data 
are represented as mean).  
(C) Cytotoxicity of CD8+ T cells transduced with FOS zipCAR containing CD3 domain 
and RR zipCAR containing the 4-1BB domain. The heat map indicates cytotoxicity at 
varying zipFv concentrations (n=3, data are represented as mean). 
(D) (Left) Isolated Treg cells were transduced with two zipCAR constructs: SYN6- CD3 
-P2A-FOXP3 and SYN1-CD28-P2A-puro. After puromycin selection (2ug/ml), Treg cells 
were co-cultured with Her2- and Axl-expressing Nalm6 target cells (Right) The heat map 
shows surface CTLA-4 expression detected after 48 hours by flow cytometry at varying 
zipFv concentrations (-Axl-SYN5 and -Her2-SYN2) (n=3, data are represented as 
mean). 
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Figure  4.6.3. The Intracellular NOT Logic with BTLA in different cell types. 
(A) Diagram of intracellular NOT logic using co-inhibitory signaling domains.  
(B) IFN- production from CD4+ T cells transduced with FOS- CD3 and RR zipCAR 
with BTLA co-inhibitory domain. Supernatants were collected 24 hours after adding 
  
126 
1.2nM -Her2-SYN9 zipFv and 12nM -Axl-EE zipFv (n=3, data are represented as the 
mean ± SD). 
(C) Effect of concentration of -Her2-SYN9 zipFv on cytotoxicity performed by FOS 
zipCAR expressing NK-92MI cells with various activating domains (n=3, data are 
represented as the mean ± SD). 
(D)  Suppression of cytotoxicity by BTLA. NK-92MI cells expressing FOS zipCAR with 
two different activating domains (CD3 and 2B4) and RR zipCAR with BTLA co-
inhibitory domain were co-cultured with Her2 and Axl expressing Nalm6 target cells in 
the presence or absence of -Axl-SYN9 and -Her2-EE. Living target cells were measured 
by flow cytometry 24 hours after starting co-culture (n=3, data are represented as the mean 
± SD). 
(E) Effect of concentration of -Her2-SYN9 and -Axl-EE zipFvs on cytotoxicity 
performed by NK-92MI cells. (Left) SUPRA CAR-engineered NK cells express RR 
zipCAR with BTLA co-inhibitory domain and  FOS zipCAR with CD3 domain (Right) 
with 2B4 activation domain (n=3, data are represented as the mean). 
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Figure  4.6.4.  Tunable 3-input multi-logic in a single cell.   
 (A) Design of orthogonal SUPRA CARs that control CD3, CD28, and BTLA signaling 
domains inducibly and independently. Primary CD8+ T cells were engineered to express 
FOS zipCAR, SYN6 zipCAR and SYN1 zipCAR that contain CD3 domain, CD28, and 
BTLA signaling domain, respectively. In addition, -Meso-SYN9 zipFv, -Axl-SYN5 
zipFv, and -SYN2-Her2 zipFv lead to activation of CD3, CD28, and BTLA, 
respectively. IFN- secretion was measured after co-culturing with Her2, Axl, and Meso 
expressing Nalm6 target cells with different zipFv combinations (n=3, data are represented 
as the mean ± SD, the statistical significance was determined by Student’s t-test, * = p 
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≤0.05). 
(B) Primary CD4+ T cells expressing FOS- CD3, SYN6-CD28, and SYN1-BTLA were 
co-cultured with Her2, Axl, and CD19 expressing Nalm6 target cells.  The 3D heat map 
shows IFN- production from 3-input CD4+ T cells at varying concentrations of three 
different corresponding zipFvs (n=3, data are represented as the mean).  
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Figure  4.6.5.  The Intercellular NOT-gate with Regulatory T (Treg) Cells.   
(A) Diagram of intercellular NOT gate with Treg cells. The RR zipCAR and FOS zipCAR 
control the activity of Treg and conventional CD4+ T cells (Tconv), respectively. α-Axl-
EE zipFv binds to RR zipCAR and activates Treg cells. α-Her2-SYN9 zipFv binds to the 
FOS zipCAR and activates CD4+ Tconv cells. Activation of Treg cells leads to suppression 
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of CD4+ Tconv cells. 
(B) Suppression of growth of CD4+ Tconv cell by SUPRA CAR equipped Treg cells. 
CD4+ Tconv cells expressing FOS zipCAR were pre-labeled with the intracellular 
CellTrace Violet dye. When activated by CAR signaling, the fluorescence intensity of 
labeled cells will decrease with cellular growth. Cells were analyzed by flow cytometer 
after 4 days of the co-culture period. The shift of peaks to leftward indicates T cell 
proliferation. Each plot shows dye fluorescence of CD4+ Tconv cells with different zipFv 
combinations (representative of three biological replicates). 
(C) Quantified proliferation measurement of FACS plot shown in Figure 5B (n=3, data are 
represented as the mean ± SD, the statistical significance was determined by Student’s t-
test, **= p ≤0.01).   
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Figure  4.6.6.  Engineering Endogenous Immune System with SUPRA CAR 
expressing different T cell subtypes.   
(A) Schematic of controlling macrophage polarization by zipCAR expressing Th1 and Th2 
cells. The RR zipCAR and FOS zipCAR control the activity of Th1 and Th2 cells, 
respectively. α-Axl-EE zipFv binds to RR zipCAR and activates Th1 cells. α-Her2-SYN9 
zipFv binds to the FOS zipCAR and activates Th2 cells. Activation of Th1 and Th2 CD4+ 
T cells leads to secretion of IFN- and IL4, respectively. Macrophage polarizes to M1 
(pro-inflammatory) when exposed to IFN- secreted by Th1 cell and it polarizes to M2 
(anti-inflammatory) when exposed to IL-4 secreted by Th2 cells. 
(B) IFN- (Top) and IL-4 (Bottom) production from RR zipCAR expressing Th1 cells and 
FOS zipCAR expressing Th2 cells with or without 5 nM anti-Her2-SYN9 zipFv and 5 nM 
anti-Axl-EE zipFv (n=3, data are represented as the mean ± SD). 
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(C) (Top) HLA-DR and CCR7 expression levels in THP-1 macrophages were measured 
by flow cytometer 24 hr after staring co-culture  (Bottom) CD206 in THP-1 macrophages 
was also analyzed at the same time as detecting M2 marker (n=3, data are represented as 
the mean ± SD).  
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Figure  4.6.7.  Different immune cell types expressing SUPRA CAR. 
(A) (Left) IFN- and IL-4 cytokine secretion from RR zipCAR expressing in vitro 
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differentiated Th1 cells (Right) IFN- and IL-4 cytokine level from RR zipCAR 
expressing in vitro differentiated Th2 cells. NALM6 cells expressing Her2 were co-
cultured with RR zipCAR expressing Th1 and Th2 cells with and without -Her2-EE zipFv 
(n=3, data are represented as mean ± SD). 
(B) Verification of the isolated CD4+CD25+highCD127low Treg. Once Treg has been 
isolated using “EasySep™ Human CD4+CD127lowCD25+ Regulatory T Cell Isolation 
Kit” (STEMCELL cat#18063), Treg surface markers (CD4, CD127, and CD25) have been 
verified using flow cytometry (Isolated Treg population is colored in green) (representative 
of three biological replicates). 
(C) Schematic of zipCAR construct used for Treg experiments. FOXP3 transcription factor 
was coexpressed with zipCAR using P2A ribosomal skipping sequence to enhance Treg 
stability.  
(D) Verification of γδ T cell surface marker after ZOL activation. Once γδ T  cells were 
isolated using EasySep™ Human Gamma/Delta T Cell Isolation Kit (STEMCELL 
Car#19255), isolated cells were activated using zoledronic acid. γδ T specific surface 
markers (both Vδ1 and Vδ2) were used to verify the expression of delta TCR from isolated 
γδ T cells. 
(E) After isolation and expansion, CAR expression was verified by expression of mCherry 
that was fused to zipCAR.  
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Figure  4.6.8 Schematics of SUPRA CARs used for 2-input AND gates. 
(A) (Left) Schematics of 2 input AND gate constructs. Fos zipCAR is used to control the 
CD3 domain and RR zipCAR is used to control CD28 or 4-1BB co-stimulatory domains. 
Both zipCARs are fused to GFP or mCherry for visualization (Right) FACS diagram that 
shows the expression of two different receptors in a single cell (representative of three 
biological replicates). 
(B) (Left) Schematics of 2 input AND gate construct designs. SYN5 zipCAR is used to 
control the CD3 domain and SYN1 zipCAR is used to control the CD28 co-stimulatory 
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domain.  FOXP3 transcription factor and puromycin resistance gene are co-expressed with 
zipCARs using P2A ribosomal skipping sequence. After transduction of primary T cells, 
cells were treated with 2ug/ml puromycin to select for positive cells (Right) FACS diagram 
that shows the expression of two different receptors in a single cell (representative of three 
biological replicates).   
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Figure  4.6.9.  Co-Inhibitory domain screening in T cells.  
(A) Schematics of co-inhibitory domain constructs. FOS zipCAR controls CD28- CD3 
domain and RR zipCAR regulates different co-inhibitory domains including PD-1, LAG3, 
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TIM3, BTLA, and CTLA-4.  
(B, C) Diagram of co-inhibitory screening in CD4+ T cells (B) and CD8+ T cells (C). 
CD4+ and CD8+ T cells are engineered to express FOS-CD28- CD3 zipCAR (binds to 
-Her2-SYN9 zipFv) and RR zipCAR (binds to -Axl-EE zipFv) with different co-
inhibitory domains. IFN- cytokine level is measured after addition of different 
combinations of zipFvs (n=3, data are represented as mean ± SD). 
(D) BTLA equipped SUPRA CD8+ T cell do not prevent the killing of target cells (n=3, 
data are represented as mean ± SD).  
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Figure  4.6.10.  Co-stimulatory and Co-Inhibitory domain screening in NK cells. 
 (A) (Left) Schematics of activating domains and co-inhibitory domain constructs used in 
NK cells. FOS zipCAR controls different activating domains including CD3, CD28- 
CD3, CD28, ICOS, 2B4, NKG2D, and DAP12. RR zipCAR regulates BTLA co-
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inhibitory domain (Right) zipCAR expression level measured by flow cytometry 
(representative of three biological replicates). 
(B) Effect of BTLA activation on different activating domains in NK cells (n=3, data are 
represented as mean ± SD).   
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Figure  4.6.11.  Orthogonal SUPRA pairs in primary human T cells and schematics 
construct designs used for 3 input logic circuit. 
 (A) Functional orthogonal SUPRA pairs in CD8+ T cells (n=3, data are represented as 
mean). 
(B) (Left) Schematics of three different zipCAR constructs used for 3 input logic circuits 
(Right) zipCAR expression level measured by flow cytometry after puromycin selection. 
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Figure  4.6.12.  Effect of recombinant cytokines on macrophage differentiation. 
(A) Effect of recombinant IFN- (10ng/ml) or IL-4 (10ng/ml) on in vitro macrophage 
differentiation measured by M1 and M2 macrophage surface markers (n=3, data are 
represented as mean ± SD). 
(B) Flow cytometry plot shown in Figures 7B and 7C. 
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